<?xml version="1.0" encoding="utf-8"?><Regulation lims:pit-date="2025-05-31" hasPreviousVersion="true" lims:lastAmendedDate="2025-05-31" lims:current-date="2025-07-24" lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128571" lims:id="1128571" gazette-part="II" regulation-type="SOR" xml:lang="en" xmlns:lims="http://justice.gc.ca/lims"><Identification lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128572" lims:id="1128572"><InstrumentNumber>SOR/2019-124</InstrumentNumber><RegistrationDate><Date><YYYY>2019</YYYY><MM>5</MM><DD>8</DD></Date></RegistrationDate><ConsolidationDate><Date><YYYY>2025</YYYY><MM>7</MM><DD>25</DD></Date></ConsolidationDate><EnablingAuthority lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128573" lims:id="1128573"><XRefExternal reference-type="act" link="F-27">FOOD AND DRUGS ACT</XRefExternal></EnablingAuthority><LongTitle lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128574" lims:id="1128574">Fees in Respect of Drugs and Medical Devices Order</LongTitle></Identification><Order lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128575" lims:id="1128575"><Provision lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128576" lims:id="1128576" format-ref="indent-0-0" language-align="yes"><Text>Whereas, pursuant to section 30.62<FootnoteRef idref="fn_a">a</FootnoteRef> of the <XRefExternal reference-type="act" link="F-27">Food and Drugs Act</XRefExternal><FootnoteRef idref="fn_b">b</FootnoteRef>, the Minister of Health has consulted with any persons that the Minister considers to be interested in the matter;</Text></Provision><Provision lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128577" lims:id="1128577" format-ref="indent-0-0" language-align="yes"><Text>Therefore, the Minister of Health, pursuant to subsections 30.61(1)<FootnoteRef idref="fn_a">a</FootnoteRef> and 30.63(1)<FootnoteRef idref="fn_a">a</FootnoteRef> of the <XRefExternal reference-type="act" link="F-27">Food and Drugs Act</XRefExternal><FootnoteRef idref="fn_b">b</FootnoteRef>, makes the annexed <XRefExternal reference-type="regulation" link="SOR-2019-124">Fees in Respect of Drugs and Medical Devices Order</XRefExternal>.</Text></Provision><Provision lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128578" lims:id="1128578" format-ref="indent-0-0" language-align="yes"><Text>Ottawa, May 3, 2019</Text><SignatureBlock justification="left" width="20pc"><SignatureName justification="left" topmarginspacing="12">Ginette C. Petitpas Taylor</SignatureName><SignatureTitle justification="left">Minister of Health</SignatureTitle></SignatureBlock></Provision><Footnote id="fn_a" placement="page" status="official"><Label>a</Label><Text>S.C. 2017, c. 20, s. 317</Text></Footnote><Footnote id="fn_b" placement="page" status="official"><Label>b</Label><Text>R.S., c. F-27</Text></Footnote></Order><Body lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128579" lims:id="1128579"><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128580" lims:id="1128580" level="1"><Label>PART 1</Label><TitleText>General</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128581" lims:id="1128581" level="2"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2025-05-31" lims:fid="1128582" lims:id="1128582"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128583" lims:id="1128583">Definitions</MarginalNote><Label>1</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128584" lims:id="1128584"><Label>(1)</Label><Text>The following definitions apply in this Order.</Text><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128585" lims:id="1128585"><Text><DefinedTermEn>entity</DefinedTermEn> has the meaning assigned by the definition <DefinitionRef>organization</DefinitionRef> in section 2 of the <XRefExternal reference-type="act" link="C-46">Criminal Code</XRefExternal>. (<DefinedTermFr>entité</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128586" lims:id="1128586"><Text><DefinedTermEn>fiscal year</DefinedTermEn> means</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1128587" lims:id="1531305"><Label>(a)</Label><Text>for the purposes of sections 16, 17, 25, 26, 27.6, 27.7, 49, 53, 57, 58.2, 66, 67, 74 and 79, the fiscal year of a person that provides information under that section or of a person with which the person is affiliated; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128588" lims:id="1128588"><Label>(b)</Label><Text>for the purposes of any other section, the period beginning on April 1 in one year and ending on March 31 in the next year. (<DefinedTermFr>exercice</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1128589" lims:id="1531304"><Text><DefinedTermEn>performance standard</DefinedTermEn> means the document entitled <XRefExternal reference-type="standard">Performance Standards for the Fees in Respect of Drugs and Medical Devices Order</XRefExternal> that is published by the Government of Canada on its website, dated February 16, 2024. (<DefinedTermFr>norme de rendement</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128590" lims:id="1128590"><Text><DefinedTermEn>small business</DefinedTermEn> means a person in respect of which either of the following criteria applies:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128591" lims:id="1128591"><Label>(a)</Label><Text>the total of the number of employees of the person and of the persons with which the person is affiliated is fewer than 100; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128592" lims:id="1128592"><Label>(b)</Label><Text>the total of the gross revenue of the person and of the persons with which the person is affiliated is $30,000 or more but less than $5 million. (<DefinedTermFr>petite entreprise</DefinedTermFr>)</Text></Paragraph></Definition></Subsection><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1128593" lims:id="1531306"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531307" lims:id="1531307">Other words and expressions</MarginalNote><Label>(2)</Label><Text>Unless the context otherwise requires, other words and expressions used in this Order have the meanings assigned to them by the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> or the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>, as the case may be.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128595" lims:id="1128595"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128596" lims:id="1128596">Affiliation</MarginalNote><Label>(3)</Label><Text>For the purposes of this Order,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128597" lims:id="1128597"><Label>(a)</Label><Text>one entity is affiliated with another entity if one of them is the subsidiary of the other or both are subsidiaries of the same entity or each of them is controlled by the same entity or individual;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128598" lims:id="1128598"><Label>(b)</Label><Text>if two entities are affiliated with the same entity at the same time, they are deemed to be affiliated with each other; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128599" lims:id="1128599"><Label>(c)</Label><Text>an individual is affiliated with an entity if the individual controls the entity.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128600" lims:id="1128600"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128601" lims:id="1128601">Subsidiary entity</MarginalNote><Label>(4)</Label><Text>For the purposes of this Order, an entity is a subsidiary of another entity if it is controlled by that other entity.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128602" lims:id="1128602"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128603" lims:id="1128603">Control</MarginalNote><Label>(5)</Label><Text>For the purposes of this Order,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128604" lims:id="1128604"><Label>(a)</Label><Text>a corporation is controlled by an entity or an individual if</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128605" lims:id="1128605"><Label>(i)</Label><Text>securities of the corporation to which are attached more than 50% of the votes that may be cast to elect directors of the corporation are held, directly or indirectly, whether through one or more subsidiaries or otherwise, other than by way of security only, by or for the benefit of that entity or individual, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128606" lims:id="1128606"><Label>(ii)</Label><Text>the votes attached to those securities are sufficient, if exercised, to elect a majority of the directors of the corporation; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128607" lims:id="1128607"><Label>(b)</Label><Text>an entity other than a corporation is controlled by an entity or individual if the entity or individual, directly or indirectly, whether through one or more subsidiaries or otherwise, holds an interest in the entity that is not a corporation that entitles them to receive more than 50% of the profits of that entity or more than 50% of its assets on dissolution.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128608" lims:id="1128608"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128609" lims:id="1128609">Deemed affiliation</MarginalNote><Label>(6)</Label><Text>For the purposes of this Order, if it may reasonably be considered that one of the main reasons for the separate existence of two or more corporations is so that one of them meets the applicable conditions for a remission of a fee fixed under this Order for which only small businesses are eligible, the two or more corporations are deemed to be affiliated with each other.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391037" lims:id="1391037" lims:enactId="1390953">SOR/2023-21, s. 1</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436524" lims:id="1436524" lims:enactId="1435005">SOR/2023-278, s. 1</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531308" lims:id="1531308" lims:enactId="1456169">SOR/2024-121, s. 1</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128610" lims:id="1128610" level="2"><TitleText>Purpose</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2025-05-31" lims:fid="1128611" lims:id="1128611"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128612" lims:id="1128612">Purpose — fees</MarginalNote><Label>2</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128613" lims:id="1128613"><Label>(1)</Label><Text>The purpose of this Order is to fix the fees for the following:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128614" lims:id="1128614"><Label>(a)</Label><Text>in respect of drugs for human use and drugs for veterinary use only, the examination of a new drug submission, a supplement to a new drug submission, an abbreviated new drug submission or a supplement to an abbreviated new drug submission referred to in section C.08.002, C.08.002.1 or C.08.003 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, as the case may be, an application in respect of an establishment licence filed under those Regulations or an application for a drug identification number filed under section C.01.014.1 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128615" lims:id="1128615"><Label>(b)</Label><Text>in respect of drugs for veterinary use only, the examination of a notification for a veterinary health product filed under subsection C.01.615(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, a preclinical submission filed under subsection C.08.005(1) of those Regulations, information filed under section C.08.010 of those Regulations for the purpose of obtaining a letter of authorization, information and material filed under section C.08.014 of those Regulations for the purpose of obtaining an experimental studies certificate, information and material filed with the Minister in respect of a notifiable change or a protocol filed with the Minister;</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531309" lims:id="1531309"><Label>(b.1)</Label><Text>in respect of biocides, the examination of an application for a market authorization submitted under section 10 of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>, an application for a notice of acceptance in respect of a major change submitted under subsection 15(2) of those Regulations, the examination of a written description of a minor change provided to the Minister under subsection 17(1) of those Regulations, other than a change to contact information referred to in paragraph (a) of the definition of <DefinitionRef>minor change</DefinitionRef> in subsection 1(1) of those Regulations or a change referred to in paragraph (f) of that definition, or the examination of an application for a market authorization for a biocide that is based on a comparison to a biocide that is authorized for sale by a foreign regulatory authority submitted under section 26 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531472" lims:id="1531472"><Label>(b.2)</Label><Text>the right to sell a biocide under the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1128616" lims:id="1391039"><Label>(c)</Label><Text>the right to sell a drug under the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1128617" lims:id="1391040"><Label>(d)</Label><Text>the examination of an application in respect of a medical device licence, the right to sell a medical device or the examination of an application in respect of an establishment licence under the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>; and</Text></Paragraph><Paragraph lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1391038" lims:id="1436534"><Label>(e)</Label><Text>the examination of an application to amend an authorization in respect of a Class II, III or IV medical device that is not a UPHN medical device or the right to sell such a device under the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128618" lims:id="1128618"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128619" lims:id="1128619">Purpose — remission</MarginalNote><Label>(2)</Label><Text>The purpose of this Order is also to remit, in whole or in part, certain of those fees.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391042" lims:id="1391042" lims:enactId="1390955">SOR/2023-21, s. 2</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436535" lims:id="1436535" lims:enactId="1435015">SOR/2023-278, s. 6</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531311" lims:id="1531311" lims:enactId="1456176">SOR/2024-121, s. 2</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128620" lims:id="1128620" level="2"><TitleText>Non-application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128621" lims:id="1128621"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128622" lims:id="1128622">Non-application</MarginalNote><Label>3</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128623" lims:id="1128623"><Label>(1)</Label><Text>This Order does not apply in respect of</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128624" lims:id="1128624"><Label>(a)</Label><Text>publicly funded health care institutions;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128625" lims:id="1128625"><Label>(b)</Label><Text>branches or agencies of the Government of Canada or of the government of a province; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128626" lims:id="1128626"><Label>(c)</Label><Text>drugs that are the subject of an extraordinary use new drug submission filed under section C.08.002.01 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> or of an abbreviated extraordinary use new drug submission filed under section C.08.002.1 of those Regulations.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128627" lims:id="1128627"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128628" lims:id="1128628">Definition of <DefinitionRef>publicly funded health care institution</DefinitionRef></MarginalNote><Label>(2)</Label><Text>For the purposes of subsection (1), <DefinedTermEn>publicly funded health care institution</DefinedTermEn> means an institution that is funded by the Government of Canada or the government of a province and that is</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128629" lims:id="1128629"><Label>(a)</Label><Text>licensed, approved or designated by a province in accordance with the laws of the province to provide care or treatment to persons or animals suffering from any form of disease or illness; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128630" lims:id="1128630"><Label>(b)</Label><Text>owned or operated by the Government of Canada or the government of a province and that provides health services.</Text></Paragraph></Subsection></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128631" lims:id="1128631" level="2"><TitleText>Annual Adjustment of Fees</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128632" lims:id="1128632"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128633" lims:id="1128633">Adjustment of fees</MarginalNote><Label>4</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128634" lims:id="1128634"><Label>(1)</Label><Text>Beginning on April 1, 2021, every fee set out in this Order is to be adjusted in each fiscal year on April 1 by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the <XRefExternal reference-type="act" link="S-19">Statistics Act</XRefExternal>, for the previous fiscal year and rounded up to the nearest dollar.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128635" lims:id="1128635"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128636" lims:id="1128636">Formula</MarginalNote><Label>(2)</Label><Text>In the case of a fee that is payable under any of Divisions 1 to 5 of Part 2 or Division 1 of Part 3 in a fiscal year that is not set out in the applicable schedule, the amount of the fee is to be calculated, on April 1 of the fiscal year, in accordance with the following formula and rounded up to the nearest dollar:</Text><FormulaGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128637" lims:id="1128637"><Formula lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128638" lims:id="1128638"><FormulaText>Fee = A + (A × B)</FormulaText></Formula><FormulaConnector>where</FormulaConnector><FormulaDefinition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128639" lims:id="1128639"><FormulaTerm>A</FormulaTerm><Text>is the amount of the fee that was payable in the previous fiscal year; and</Text></FormulaDefinition><FormulaDefinition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128640" lims:id="1128640"><FormulaTerm>B</FormulaTerm><Text>is the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the <XRefExternal reference-type="act" link="S-19">Statistics Act</XRefExternal>, for the previous fiscal year.</Text></FormulaDefinition></FormulaGroup></Subsection></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128641" lims:id="1128641" level="2"><TitleText>Requests for Information — Remissions for Small Businesses</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2025-05-31" lims:fid="1128642" lims:id="1128642"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128643" lims:id="1128643">Information on request</MarginalNote><Label>5</Label><Text>If the Minister determines, in respect of a person that provided information under any of the following provisions, that additional information is necessary to demonstrate that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection 1(1) in the applicable fiscal year, the Minister may request that the person provide him or her with additional information within 60 days after the day on which the request is made:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128644" lims:id="1128644"><Label>(a)</Label><Text>subparagraph <XRefInternal>16</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128645" lims:id="1128645"><Label>(b)</Label><Text>clause <XRefInternal>17</XRefInternal>(b)(i)(B) or (ii)(B);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128646" lims:id="1128646"><Label>(c)</Label><Text>subparagraph <XRefInternal>25</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128647" lims:id="1128647"><Label>(d)</Label><Text>clause <XRefInternal>26</XRefInternal>(b)(i)(B) or (ii)(B);</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531312" lims:id="1531312"><Label>(d.1)</Label><Text>subparagraph <XRefInternal>27.6</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531313" lims:id="1531313"><Label>(d.2)</Label><Text>clause <XRefInternal>27.7</XRefInternal>(b)(i)(B) or (ii)(B);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128648" lims:id="1128648"><Label>(e)</Label><Text>subparagraph <XRefInternal>49</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128649" lims:id="1128649"><Label>(f)</Label><Text>subparagraph <XRefInternal>53</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128650" lims:id="1128650"><Label>(g)</Label><Text>subparagraph <XRefInternal>57</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531314" lims:id="1531314"><Label>(g.1)</Label><Text>subparagraph <XRefInternal>58.2</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128651" lims:id="1128651"><Label>(h)</Label><Text>subparagraph <XRefInternal>66</XRefInternal>(a)(ii) or (b)(ii);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128652" lims:id="1128652"><Label>(i)</Label><Text>clause <XRefInternal>67</XRefInternal>(b)(i)(B) or (ii)(B);</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128653" lims:id="1128653"><Label>(j)</Label><Text>subparagraph <XRefInternal>74</XRefInternal>(a)(ii) or (b)(ii); or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128654" lims:id="1128654"><Label>(k)</Label><Text>subparagraph <XRefInternal>79</XRefInternal>(a)(ii) or (b)(ii).</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531316" lims:id="1531316" lims:enactId="1456178">SOR/2024-121, s. 3</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128655" lims:id="1128655" level="2"><TitleText>Performance Standard and Remission</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2024-12-18" lims:fid="1128656" lims:id="1128656"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128657" lims:id="1128657">Remission — performance standard</MarginalNote><Label>6</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128658" lims:id="1128658"><Label>(1)</Label><Text>If the Minister determines that the performance standard has not been met in relation to a fee that is payable under this Order, remission is granted to the person that must pay the fee</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128659" lims:id="1128659"><Label>(a)</Label><Text>of an amount equal to 25% of the fee; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128660" lims:id="1128660"><Label>(b)</Label><Text>of an amount equal to 25% of the amount that is payable, in the case where remission is granted of part of the fee under any other provision of this Order.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128661" lims:id="1128661"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128662" lims:id="1128662">Exceptions</MarginalNote><Label>(2)</Label><Text>Subsection (1) does not apply to a fee for the examination of</Text><Paragraph lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1128663" lims:id="1289563"><Label>(a)</Label><Text>an application or submission referred to in this Order in respect of which a joint or parallel review is conducted by the Minister and a foreign regulatory authority;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128664" lims:id="1128664"><Label>(b)</Label><Text>an application for a licence that is filed under section 32 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> if</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128665" lims:id="1128665"><Label>(i)</Label><Text>the medical device to which the application relates includes a component that is a drug, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1128666" lims:id="1289564"><Label>(ii)</Label><Text>the Minister has made a decision in respect of the application to issue or amend a medical device licence under section 36 of those Regulations, or to refuse to issue or amend such a licence under section 38 of those Regulations; or</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1289562" lims:id="1505065"><Label>(c)</Label><Text>the following:</Text><Subparagraph lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1505066" lims:id="1505066"><Label>(i)</Label><Text>a new drug submission for a public health emergency drug if subsection C.08.002(2.3) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> applies to that submission, or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1505067" lims:id="1505067"><Label>(ii)</Label><Text>a supplement to any new drug submission if subsection C.08.003(7) of those Regulations applies to that supplement.</Text></Subparagraph></Paragraph></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289566" lims:id="1289566" lims:enactId="1289164">SOR/2021-47, s. 1</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391043" lims:id="1391043" lims:enactId="1390957">SOR/2023-21, s. 3(F)</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1505068" lims:id="1505068" lims:enactId="1496987">SOR/2024-247, s. 1</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128667" lims:id="1128667" level="1"><Label>PART 2</Label><TitleText>Drugs</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128668" lims:id="1128668" level="2"><Label>DIVISION 1</Label><TitleText>Fees for Examination of a Submission — Drugs for Human Use</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128669" lims:id="1128669" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128670" lims:id="1128670"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128671" lims:id="1128671">Definition of <DefinitionRef>submission</DefinitionRef></MarginalNote><Label>7</Label><Text>In this Division, <DefinedTermEn>submission</DefinedTermEn> means any of the following:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128672" lims:id="1128672"><Label>(a)</Label><Text>an application for a drug identification number that is filed under section C.01.014.1 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128673" lims:id="1128673"><Label>(b)</Label><Text>a new drug submission that is filed under section C.08.002 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128674" lims:id="1128674"><Label>(c)</Label><Text>an abbreviated new drug submission that is filed under section C.08.002.1 of those Regulations; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128675" lims:id="1128675"><Label>(d)</Label><Text>a supplement to a new drug submission or abbreviated new drug submission that is filed under section C.08.003 of those Regulations.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128676" lims:id="1128676" level="3"><TitleText>Non-application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128677" lims:id="1128677"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128678" lims:id="1128678">Non-application</MarginalNote><Label>8</Label><Text>This Division does not apply to drugs for veterinary use only.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128679" lims:id="1128679" level="3"><TitleText>Fees and Remissions</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128680" lims:id="1128680"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128681" lims:id="1128681">Fee for examination</MarginalNote><Label>9</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128682" lims:id="1128682"><Label>(1)</Label><Text>Subject to paragraph <XRefInternal>10</XRefInternal>(b) and section <XRefInternal>12</XRefInternal>, the fee for the examination of a submission is, in respect of the applicable submission class set out in column 1 of Schedule 1 and described in column 2, as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128683" lims:id="1128683"><Label>(a)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 6 of Schedule 1, the fee set out in that column; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128684" lims:id="1128684"><Label>(b)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 6 of Schedule 1, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128685" lims:id="1128685"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128686" lims:id="1128686">Fee paid by person that files submission</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the submission.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128687" lims:id="1128687"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128688" lims:id="1128688">Fee and timing of payment — preliminary examination</MarginalNote><Label>10</Label><Text>If a preliminary examination is conducted in respect of a submission,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128689" lims:id="1128689"><Label>(a)</Label><Text>the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) stating that the submission has been found to be complete and has been accepted for further examination; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128690" lims:id="1128690"><Label>(b)</Label><Text>10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) stating that the submission has been found to be incomplete.</Text></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128691" lims:id="1128691"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128692" lims:id="1128692">Fee and timing of payment — no preliminary examination</MarginalNote><Label>11</Label><Text>If a preliminary examination is not conducted in respect of a submission, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) stating that the submission has been received.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128693" lims:id="1128693"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128694" lims:id="1128694">Fee — filing in previous fiscal year</MarginalNote><Label>12</Label><Text>For the purposes of subsection <XRefInternal>9</XRefInternal>(1), if the Minister issues a notice referred to in section <XRefInternal>10</XRefInternal> or <XRefInternal>11</XRefInternal> in the fiscal year that follows the fiscal year in which the submission was filed, the fee that is payable is the fee that was payable in the fiscal year in which the submission was filed.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128695" lims:id="1128695"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128696" lims:id="1128696">Deferred payment — notice of compliance</MarginalNote><Label>13</Label><Text>Despite sections <XRefInternal>10</XRefInternal> and <XRefInternal>11</XRefInternal>, if the person referred to in subsection <XRefInternal>9</XRefInternal>(2) files an application for authorization under section C.07.003 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> at the same time that the person files the submission, payment of the fee is deferred until the issuance to the person of a notice of compliance under section C.08.004 of those Regulations or of a document setting out the drug identification number assigned for the drug under subsection C.01.014.2(1) of those Regulations.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2021-03-19" lims:fid="1128697" lims:id="1128697"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128698" lims:id="1128698">Remission — urgent public health need</MarginalNote><Label>14</Label><Text>Remission is granted to a person referred to in subsection <XRefInternal>9</XRefInternal>(2) that files a new drug submission under section C.08.002 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> or an application for a drug identification number under section C.01.014.1 of those Regulations of the amount of the fee that is payable under subsection <XRefInternal>9</XRefInternal>(1) if, as of the day on which the person filed the new drug submission or application,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128699" lims:id="1128699"><Label>(a)</Label><Text>the drug has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form as a drug that may be imported under subsection C.10.001(2) of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128700" lims:id="1128700"><Label>(b)</Label><Text>a drug identification number has not been assigned under subsection C.01.014.2(1) of those Regulations for the drug or for another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128701" lims:id="1128701"><Label>(c)</Label><Text>a notice of compliance has not been issued under section C.08.004 of those Regulations in respect of the drug or another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form.</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289568" lims:id="1289568" lims:enactId="1289166">SOR/2021-47, s. 2(F)</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:lastAmendedDate="2024-12-18" lims:fid="1289569" lims:id="1289569"><MarginalNote lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289570" lims:id="1289570">Remission — designated COVID-19 drug</MarginalNote><Label>14.1</Label><Subsection lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289571" lims:id="1289571"><Label>(1)</Label><Text>Remission is granted to the person referred to in subsection 9(2) of the amount of the fee that is payable under subsection 9(1) if the person has</Text><Paragraph lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1289572" lims:id="1505069"><Label>(a)</Label><Text>filed, under the ISAD Interim Order, an application for a <DefinitionRef>designated COVID-19 drug</DefinitionRef>, as defined in section C.08.001.1 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> as that section read immediately before the day on which subsection <XRefInternal>24</XRefInternal>(1) of the <XRefExternal reference-type="regulation">Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing)</XRefExternal> comes into force; and</Text></Paragraph><Paragraph lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289573" lims:id="1289573"><Label>(b)</Label><Text>subsequently filed a submission for that drug.</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1289574" lims:id="1505070"><MarginalNote lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1505071" lims:id="1505071">Remission — no previous submission</MarginalNote><Label>(2)</Label><Text>The remission referred to in subsection (1) is granted if the person has not previously filed a submission for that designated COVID-19 drug.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289577" lims:id="1289577" lims:enactId="1289168">SOR/2021-47, s. 3</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-12-18" lims:enacted-date="2024-12-04" lims:fid="1505072" lims:id="1505072" lims:enactId="1496989">SOR/2024-247, s. 2</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128702" lims:id="1128702"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128703" lims:id="1128703">Remission — General Council Decision</MarginalNote><Label>15</Label><Text>Remission is granted to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) of the amount of the fee that is payable under subsection <XRefInternal>9</XRefInternal>(1) if the person has received an authorization under section 21.04 of the <XRefExternal reference-type="act" link="P-4">Patent Act</XRefExternal> in respect of the drug.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128704" lims:id="1128704"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128705" lims:id="1128705">Remission — small business</MarginalNote><Label>16</Label><Text>Subject to section <XRefInternal>18</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) of an amount equal to 50% of the fee that is payable under subsection <XRefInternal>9</XRefInternal>(1) if the person provides with their submission, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128706" lims:id="1128706"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128707" lims:id="1128707"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128708" lims:id="1128708"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128709" lims:id="1128709"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128710" lims:id="1128710"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128711" lims:id="1128711"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128712" lims:id="1128712"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128713" lims:id="1128713"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128714" lims:id="1128714"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection 1(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128715" lims:id="1128715"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128716" lims:id="1128716"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128717" lims:id="1128717"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128718" lims:id="1128718"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128719" lims:id="1128719"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2025-05-31" lims:fid="1128720" lims:id="1128720"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128721" lims:id="1128721">Remission — first submission by small business</MarginalNote><Label>17</Label><Text>Subject to section <XRefInternal>18</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>9</XRefInternal>(2) of an amount equal to the fee that is payable under subsection <XRefInternal>9</XRefInternal>(1) if the following conditions are met:</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1128722" lims:id="1531317"><Label>(a)</Label><Text>the person has not previously filed</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531318" lims:id="1531318"><Label>(i)</Label><Text>a submission in respect of a drug; or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531319" lims:id="1531319"><Label>(ii)</Label><Text>an <DefinitionRef>application</DefinitionRef> as defined in section <XRefInternal>27.1</XRefInternal> in respect of a biocide; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128723" lims:id="1128723"><Label>(b)</Label><Text>the person provides with their submission, in a form established by the Minister,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128724" lims:id="1128724"><Label>(i)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128725" lims:id="1128725"><Label>(A)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128726" lims:id="1128726"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128727" lims:id="1128727"><Label>(I)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128728" lims:id="1128728"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128729" lims:id="1128729"><Label>(III)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128730" lims:id="1128730"><Label>(IV)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause></Clause></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128731" lims:id="1128731"><Label>(ii)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128732" lims:id="1128732"><Label>(A)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection 1(1) in their first fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128733" lims:id="1128733"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128734" lims:id="1128734"><Label>(I)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128735" lims:id="1128735"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128736" lims:id="1128736"><Label>(III)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128737" lims:id="1128737"><Label>(IV)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Subclause></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531321" lims:id="1531321" lims:enactId="1456183">SOR/2024-121, s. 4</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128738" lims:id="1128738"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128739" lims:id="1128739">Fee or difference payable</MarginalNote><Label>18</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>9</XRefInternal>(2) provide additional information, the fee — or the difference between the fee payable under subsection <XRefInternal>9</XRefInternal>(1) and the amount already paid, as the case may be — is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128740" lims:id="1128740"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128741" lims:id="1128741"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128742" lims:id="1128742" level="2"><Label>DIVISION 2</Label><TitleText>Fees for Examination of a Submission — Drugs for Veterinary Use Only</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128743" lims:id="1128743" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128744" lims:id="1128744"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128745" lims:id="1128745">Definition of <DefinitionRef>submission</DefinitionRef></MarginalNote><Label>19</Label><Text>In this Division, <DefinedTermEn>submission</DefinedTermEn> means any of the following:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128746" lims:id="1128746"><Label>(a)</Label><Text>an application for a drug identification number that is filed under section C.01.014.1 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128747" lims:id="1128747"><Label>(b)</Label><Text>a notification that is filed under subsection C.01.615(1) of those Regulations in respect of a veterinary health product;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128748" lims:id="1128748"><Label>(c)</Label><Text>a new drug submission that is filed under section C.08.002 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128749" lims:id="1128749"><Label>(d)</Label><Text>an abbreviated new drug submission that is filed under section C.08.002.1 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128750" lims:id="1128750"><Label>(e)</Label><Text>a supplement to a new drug submission or an abbreviated new drug submission that is filed under section C.08.003 of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128751" lims:id="1128751"><Label>(f)</Label><Text>a preclinical submission that is filed under subsection C.08.005(1) of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128752" lims:id="1128752"><Label>(g)</Label><Text>information that is filed under section C.08.010 of those Regulations for the purpose of obtaining a letter of authorization;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128753" lims:id="1128753"><Label>(h)</Label><Text>information and material that is filed under section C.08.014 of those Regulations for the purpose of obtaining an experimental studies certificate;</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128754" lims:id="1128754"><Label>(i)</Label><Text>information and material that is filed with the Minister in respect of a notifiable change; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128755" lims:id="1128755"><Label>(j)</Label><Text>a protocol that is filed with the Minister and may support any of the matters referred to in paragraphs (c) to (f) or (h).</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128756" lims:id="1128756" level="3"><TitleText>Application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128757" lims:id="1128757"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128758" lims:id="1128758">Application</MarginalNote><Label>20</Label><Text>This Division applies to drugs for veterinary use only.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128759" lims:id="1128759" level="3"><TitleText>Fees and Remissions</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128760" lims:id="1128760"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128761" lims:id="1128761">Fee for examination</MarginalNote><Label>21</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128762" lims:id="1128762"><Label>(1)</Label><Text>Subject to paragraph <XRefInternal>22</XRefInternal>(b) and section <XRefInternal>24</XRefInternal>, the fee that is payable in respect of a submission that is of a type set out in column 1 of Schedule 2, for the examination of each component set out in column 2 that is included in the submission, is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128763" lims:id="1128763"><Label>(a)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 9 of Schedule 2, the applicable fee set out in that column; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128764" lims:id="1128764"><Label>(b)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 9 of Schedule 2, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128765" lims:id="1128765"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128766" lims:id="1128766">Fee paid by person that files submission</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the submission.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128767" lims:id="1128767"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128768" lims:id="1128768">Fee and timing of payment — preliminary examination</MarginalNote><Label>22</Label><Text>If a preliminary examination is conducted in respect of a submission,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128769" lims:id="1128769"><Label>(a)</Label><Text>the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>21</XRefInternal>(2) stating that the submission has been found to be complete and has been accepted for further examination; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128770" lims:id="1128770"><Label>(b)</Label><Text>10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>21</XRefInternal>(2) stating that the submission has been found to be incomplete.</Text></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128771" lims:id="1128771"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128772" lims:id="1128772">Fee and timing of payment — no preliminary examination</MarginalNote><Label>23</Label><Text>If a preliminary examination is not conducted in respect of a submission, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>21</XRefInternal>(2) stating that the submission has been received.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128773" lims:id="1128773"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128774" lims:id="1128774">Fee — filing in previous fiscal year</MarginalNote><Label>24</Label><Text>For the purposes of subsection <XRefInternal>21</XRefInternal>(1), if the Minister issues a notice referred to in section <XRefInternal>22</XRefInternal> or <XRefInternal>23</XRefInternal> in the fiscal year that follows the fiscal year in which the submission was filed, the fee that is payable is the fee that was payable in the fiscal year in which the submission was filed.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128775" lims:id="1128775"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128776" lims:id="1128776">Remission — small business</MarginalNote><Label>25</Label><Text>Subject to section <XRefInternal>27</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>21</XRefInternal>(2) of an amount equal to 50% of the fee that is payable under subsection <XRefInternal>21</XRefInternal>(1) if the person provides with their submission, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128777" lims:id="1128777"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128778" lims:id="1128778"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128779" lims:id="1128779"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128780" lims:id="1128780"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128781" lims:id="1128781"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128782" lims:id="1128782"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128783" lims:id="1128783"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128784" lims:id="1128784"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128785" lims:id="1128785"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128786" lims:id="1128786"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128787" lims:id="1128787"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128788" lims:id="1128788"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128789" lims:id="1128789"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128790" lims:id="1128790"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2025-05-31" lims:fid="1128791" lims:id="1128791"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128792" lims:id="1128792">Remission — first submission by small business</MarginalNote><Label>26</Label><Text>Subject to section <XRefInternal>27</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>21</XRefInternal>(2) of an amount equal to the fee that is payable under subsection <XRefInternal>21</XRefInternal>(1) if the following conditions are met:</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1128793" lims:id="1531322"><Label>(a)</Label><Text>the person has not previously filed</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531323" lims:id="1531323"><Label>(i)</Label><Text>a submission in respect of a drug; or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531324" lims:id="1531324"><Label>(ii)</Label><Text>an <DefinitionRef>application</DefinitionRef> as defined in section <XRefInternal>27.1</XRefInternal> in respect of a biocide; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128794" lims:id="1128794"><Label>(b)</Label><Text>the person provides with their submission, in a form established by the Minister,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128795" lims:id="1128795"><Label>(i)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128796" lims:id="1128796"><Label>(A)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128797" lims:id="1128797"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128798" lims:id="1128798"><Label>(I)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128799" lims:id="1128799"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128800" lims:id="1128800"><Label>(III)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128801" lims:id="1128801"><Label>(IV)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause></Clause></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128802" lims:id="1128802"><Label>(ii)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128803" lims:id="1128803"><Label>(A)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection 1(1) in their first fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128804" lims:id="1128804"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128805" lims:id="1128805"><Label>(I)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128806" lims:id="1128806"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128807" lims:id="1128807"><Label>(III)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128808" lims:id="1128808"><Label>(IV)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Subclause></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531326" lims:id="1531326" lims:enactId="1456185">SOR/2024-121, s. 5</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128809" lims:id="1128809"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128810" lims:id="1128810">Fee or difference payable</MarginalNote><Label>27</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>21</XRefInternal>(2) provide additional information, the fee — or the difference between the fee payable under subsection <XRefInternal>21</XRefInternal>(1) and the amount already paid, as the case may be — is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128811" lims:id="1128811"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128812" lims:id="1128812"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531327" lims:id="1531327" level="2"><Label>DIVISION 2.1</Label><TitleText>Fees for Examination of an Application — Biocides</TitleText></Heading><Heading lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531328" lims:id="1531328" level="3"><TitleText>Definition</TitleText></Heading><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531329" lims:id="1531329"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531330" lims:id="1531330">Definition of <DefinitionRef>application</DefinitionRef></MarginalNote><Label>27.1</Label><Text>In this Division, <DefinedTermEn>application</DefinedTermEn> means any of the following:</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531331" lims:id="1531331"><Label>(a)</Label><Text>an application for a market authorization for a biocide submitted under section 10 of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>;</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531332" lims:id="1531332"><Label>(b)</Label><Text>an application for a notice of acceptance in respect of a major change submitted under subsection 15(2) of those Regulations;</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531333" lims:id="1531333"><Label>(c)</Label><Text>a written description of a minor change provided under subsection 17(1) of those Regulations, other than a change to contact information referred to in paragraph (a) of the definition of <DefinitionRef>minor change</DefinitionRef> in subsection 1(1) of those Regulations, or a change referred to in paragraph (f) of that definition;</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531334" lims:id="1531334"><Label>(d)</Label><Text>an application for a market authorization for a biocide that is based on a comparison to a biocide that is authorized for sale by a foreign regulatory authority submitted under section 26 of those Regulations.</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531336" lims:id="1531336" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531337" lims:id="1531337" level="3"><TitleText>Fees and Remissions</TitleText></Heading><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531345" lims:id="1531345"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531346" lims:id="1531346">Fee for examination</MarginalNote><Label>27.2</Label><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531347" lims:id="1531347"><Label>(1)</Label><Text>Subject to paragraph <XRefInternal>27.3</XRefInternal>(b) and section <XRefInternal>27.5</XRefInternal>, the fee for the examination of an application in respect of a class set out in column 1 of Schedule 2.1 and described in column 2 is the fee set out in column 3 of that Schedule.</Text></Subsection><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531348" lims:id="1531348"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531349" lims:id="1531349">Fee paid by Person that files application</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the application.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531351" lims:id="1531351" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531352" lims:id="1531352"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531353" lims:id="1531353">Fee and timing of payment — Preliminary examination</MarginalNote><Label>27.3</Label><Text>If a preliminary examination is conducted in respect of an application,</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531354" lims:id="1531354"><Label>(a)</Label><Text>the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) stating that the application has been found to be complete and has been accepted for further examination; or</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531355" lims:id="1531355"><Label>(b)</Label><Text>10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) stating that the application has been found to be incomplete.</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531357" lims:id="1531357" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531358" lims:id="1531358"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531359" lims:id="1531359">Fee and timing of payment — No preliminary examination</MarginalNote><Label>27.4</Label><Text>If a preliminary examination is not conducted in respect of an application, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) stating that the application has been received.</Text><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531361" lims:id="1531361" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531362" lims:id="1531362"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531363" lims:id="1531363">Fee — filing in previous fiscal year</MarginalNote><Label>27.5</Label><Text>For the purposes of subsection <XRefInternal>27.2</XRefInternal>(1), if the Minister issues a notice referred to in section <XRefInternal>27.3</XRefInternal> or <XRefInternal>27.4</XRefInternal> in the fiscal year that follows the fiscal year in which the application was filed, the fee that is payable is the fee that was payable in the fiscal year in which the application was filed.</Text><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531365" lims:id="1531365" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531366" lims:id="1531366"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531367" lims:id="1531367">Remission — small business</MarginalNote><Label>27.6</Label><Text>Subject to section <XRefInternal>27.8</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) of an amount equal to 50% of the fee that is payable under subsection <XRefInternal>27.2</XRefInternal>(1) if the person provides with their application, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531368" lims:id="1531368"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531369" lims:id="1531369"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531370" lims:id="1531370"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531371" lims:id="1531371"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531372" lims:id="1531372"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531373" lims:id="1531373"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531374" lims:id="1531374"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531375" lims:id="1531375"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531376" lims:id="1531376"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531377" lims:id="1531377"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531378" lims:id="1531378"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531379" lims:id="1531379"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531380" lims:id="1531380"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531381" lims:id="1531381"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531383" lims:id="1531383" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531384" lims:id="1531384"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531385" lims:id="1531385">Remission — first application by small business</MarginalNote><Label>27.7</Label><Text>Subject to section <XRefInternal>27.8</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) of an amount equal to the fee that is payable under subsection <XRefInternal>27.2</XRefInternal>(1) if the following conditions are met:</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531386" lims:id="1531386"><Label>(a)</Label><Text>the person has not previously filed</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531387" lims:id="1531387"><Label>(i)</Label><Text>an application in respect of a biocide;</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531388" lims:id="1531388"><Label>(ii)</Label><Text>a <DefinitionRef>submission</DefinitionRef> as defined in section <XRefInternal>7</XRefInternal> in respect of a drug; or</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531389" lims:id="1531389"><Label>(iii)</Label><Text>a <DefinitionRef>submission</DefinitionRef> as defined in section <XRefInternal>19</XRefInternal> in respect of a drug; and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531390" lims:id="1531390"><Label>(b)</Label><Text>the person provides with their application, in a form established by the Minister,</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531391" lims:id="1531391"><Label>(i)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531392" lims:id="1531392"><Label>(A)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531393" lims:id="1531393"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531394" lims:id="1531394"><Label>(I)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531395" lims:id="1531395"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531396" lims:id="1531396"><Label>(III)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531397" lims:id="1531397"><Label>(IV)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause></Clause></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531398" lims:id="1531398"><Label>(ii)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531399" lims:id="1531399"><Label>(A)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531400" lims:id="1531400"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531401" lims:id="1531401"><Label>(I)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531402" lims:id="1531402"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531403" lims:id="1531403"><Label>(III)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531404" lims:id="1531404"><Label>(IV)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Subclause></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531406" lims:id="1531406" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531407" lims:id="1531407"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531408" lims:id="1531408">Fee or difference payable</MarginalNote><Label>27.8</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>27.2</XRefInternal>(2) provide additional information, the fee — or the difference between the fee payable under subsection <XRefInternal>27.2</XRefInternal>(1) and the amount already paid, as the case may be — is immediately payable if</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531409" lims:id="1531409"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information, for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531410" lims:id="1531410"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information, for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531412" lims:id="1531412" lims:enactId="1456187">SOR/2024-121, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128813" lims:id="1128813" level="2"><Label>DIVISION 3</Label><TitleText>Fees for Examination of an Application for an Establishment Licence — Drugs</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128814" lims:id="1128814" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128815" lims:id="1128815"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128816" lims:id="1128816">Definitions</MarginalNote><Label>28</Label><Text>The following definitions apply in this Division.</Text><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128817" lims:id="1128817"><Text><DefinedTermEn>activity</DefinedTermEn> means an activity set out in Table I to section C.01A.008 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>. (<DefinedTermFr>activité</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128818" lims:id="1128818"><Text><DefinedTermEn>drug</DefinedTermEn> has the same meaning as in subsection C.01A.001(2) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>. (<DefinedTermFr>drogue</DefinedTermFr>)</Text></Definition><Definition lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128819" lims:id="1128819"><Text><DefinedTermEn>establishment licence</DefinedTermEn> means a licence issued under section C.01A.008 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>. (<DefinedTermFr>licence d’établissement</DefinedTermFr>)</Text></Definition></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128820" lims:id="1128820" level="3"><TitleText>Fees and Remission</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128821" lims:id="1128821"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128822" lims:id="1128822">Fee for examination</MarginalNote><Label>29</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128823" lims:id="1128823"><Label>(1)</Label><Text>Subject to section <XRefInternal>48</XRefInternal>, the fee for the examination of an application for an establishment licence or for the annual review of an establishment licence is the sum of the applicable fees referred to in sections <XRefInternal>33</XRefInternal> to <XRefInternal>40</XRefInternal> and the fee payable for the examination of an application to amend an establishment licence to add a building is the sum of the applicable fees referred to in sections <XRefInternal>41</XRefInternal> to <XRefInternal>47</XRefInternal>.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128824" lims:id="1128824"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128825" lims:id="1128825">Fee paid by person that files application</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the application.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128826" lims:id="1128826"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128827" lims:id="1128827">Timing of payment</MarginalNote><Label>30</Label><Text>The fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>29</XRefInternal>(2) stating that the application has been accepted for further examination.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128828" lims:id="1128828"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128829" lims:id="1128829">Reinstatement</MarginalNote><Label>31</Label><Text>Every provision of this Division that applies to an application for an establishment licence also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128830" lims:id="1128830"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128831" lims:id="1128831">Interpretation</MarginalNote><Label>32</Label><Text>In sections <XRefInternal>33</XRefInternal> to <XRefInternal>39</XRefInternal>, a reference to the examination of an application for an establishment licence includes an examination of an application for the annual review of an establishment licence.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128832" lims:id="1128832"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128833" lims:id="1128833">Fee — licence authorizing sterile fabrication</MarginalNote><Label>33</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including fabricating drugs in sterile dosage form, the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128834" lims:id="1128834"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128835" lims:id="1128835"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 1 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128836" lims:id="1128836"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128837" lims:id="1128837"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128838" lims:id="1128838"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 1 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128839" lims:id="1128839"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128840" lims:id="1128840"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128841" lims:id="1128841">Fee — licence authorizing importation</MarginalNote><Label>34</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including importing drugs — but not fabricating drugs in sterile dosage form — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128842" lims:id="1128842"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128843" lims:id="1128843"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 2 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128844" lims:id="1128844"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128845" lims:id="1128845"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128846" lims:id="1128846"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 2 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128847" lims:id="1128847"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128848" lims:id="1128848"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128849" lims:id="1128849">Fee — licence authorizing non-sterile fabrication</MarginalNote><Label>35</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including fabricating drugs that are not in sterile dosage form — but not fabricating drugs in sterile dosage form or importing drugs — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128850" lims:id="1128850"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128851" lims:id="1128851"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 3 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128852" lims:id="1128852"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128853" lims:id="1128853"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128854" lims:id="1128854"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 3 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128855" lims:id="1128855"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128856" lims:id="1128856"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128857" lims:id="1128857">Fee — licence authorizing distribution</MarginalNote><Label>36</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including distributing drugs — but not fabricating drugs in sterile dosage form, importing drugs or fabricating drugs that are not in sterile dosage form — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128858" lims:id="1128858"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128859" lims:id="1128859"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 4 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128860" lims:id="1128860"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128861" lims:id="1128861"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128862" lims:id="1128862"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 4 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128863" lims:id="1128863"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128864" lims:id="1128864"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128865" lims:id="1128865">Fee — licence authorizing wholesaling</MarginalNote><Label>37</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including wholesaling drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form or distributing drugs — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128866" lims:id="1128866"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128867" lims:id="1128867"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 5 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128868" lims:id="1128868"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128869" lims:id="1128869"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128870" lims:id="1128870"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 5 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128871" lims:id="1128871"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128872" lims:id="1128872"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128873" lims:id="1128873">Fee — licence authorizing packaging/labelling</MarginalNote><Label>38</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including packaging/labelling drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form, distributing drugs or wholesaling drugs — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128874" lims:id="1128874"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128875" lims:id="1128875"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 6 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128876" lims:id="1128876"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128877" lims:id="1128877"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128878" lims:id="1128878"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 6 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128879" lims:id="1128879"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128880" lims:id="1128880"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128881" lims:id="1128881">Fee — licence authorizing testing</MarginalNote><Label>39</Label><Text>For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including testing drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form, distributing drugs, wholesaling drugs or packaging/labelling drugs — the fee is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128882" lims:id="1128882"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128883" lims:id="1128883"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 7 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128884" lims:id="1128884"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128885" lims:id="1128885"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128886" lims:id="1128886"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 7 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128887" lims:id="1128887"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128888" lims:id="1128888"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128889" lims:id="1128889">Fee — application for licence — building outside Canada</MarginalNote><Label>40</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128890" lims:id="1128890"><Label>(1)</Label><Text>For the examination of an application for an establishment licence referred to in section <XRefInternal>33</XRefInternal> or <XRefInternal>34</XRefInternal>, the fee for each building located outside Canada that is listed on the application is</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128891" lims:id="1128891"><Label>(a)</Label><Text>in respect of drugs for human use, $918; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128892" lims:id="1128892"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128893" lims:id="1128893"><Label>(i)</Label><Text>in the case of a fee that is payable in the fiscal year 2020-2021, $765; and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128894" lims:id="1128894"><Label>(ii)</Label><Text>in the case of a fee that is payable in any subsequent fiscal year, $918.</Text></Subparagraph></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128895" lims:id="1128895"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128896" lims:id="1128896">Fee — application for annual review — building outside Canada</MarginalNote><Label>(2)</Label><Text>For the examination of an application for the annual review of an establishment licence referred to in section <XRefInternal>33</XRefInternal> or <XRefInternal>34</XRefInternal>, the fee for each building located outside Canada that is listed on the establishment licence is the applicable fee set out in paragraph (1)(a) or (b).</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128897" lims:id="1128897"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128898" lims:id="1128898">Fee — amendment — licence authorizing sterile fabrication</MarginalNote><Label>41</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to fabricate drugs in sterile dosage form at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128899" lims:id="1128899"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128900" lims:id="1128900"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 1 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128901" lims:id="1128901"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128902" lims:id="1128902"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128903" lims:id="1128903"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 1 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128904" lims:id="1128904"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128905" lims:id="1128905"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128906" lims:id="1128906">Fee — amendment — licence authorizing importation</MarginalNote><Label>42</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to import drugs — but not to fabricate drugs in sterile dosage form — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128907" lims:id="1128907"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128908" lims:id="1128908"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 2 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128909" lims:id="1128909"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128910" lims:id="1128910"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128911" lims:id="1128911"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 2 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128912" lims:id="1128912"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128913" lims:id="1128913"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128914" lims:id="1128914">Fee — amendment — licence authorizing non-sterile fabrication</MarginalNote><Label>43</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to fabricate drugs that are not in sterile dosage form — but not to fabricate drugs in sterile dosage form or import drugs — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128915" lims:id="1128915"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128916" lims:id="1128916"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 3 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128917" lims:id="1128917"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128918" lims:id="1128918"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128919" lims:id="1128919"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 3 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128920" lims:id="1128920"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128921" lims:id="1128921"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128922" lims:id="1128922">Fee — amendment — licence authorizing distribution</MarginalNote><Label>44</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to distribute drugs — but not to fabricate drugs in sterile dosage form, import drugs or fabricate drugs that are not in sterile dosage form — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128923" lims:id="1128923"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128924" lims:id="1128924"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 4 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128925" lims:id="1128925"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128926" lims:id="1128926"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128927" lims:id="1128927"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 4 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128928" lims:id="1128928"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128929" lims:id="1128929"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128930" lims:id="1128930">Fee — amendment — licence authorizing wholesaling</MarginalNote><Label>45</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to wholesale drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form or distribute drugs — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128931" lims:id="1128931"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128932" lims:id="1128932"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 5 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128933" lims:id="1128933"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128934" lims:id="1128934"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128935" lims:id="1128935"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 5 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128936" lims:id="1128936"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128937" lims:id="1128937"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128938" lims:id="1128938">Fee — amendment — licence authorizing packaging/labelling</MarginalNote><Label>46</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to package/label drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form, distribute drugs or wholesale drugs — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128939" lims:id="1128939"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128940" lims:id="1128940"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 6 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128941" lims:id="1128941"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128942" lims:id="1128942"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128943" lims:id="1128943"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 6 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128944" lims:id="1128944"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128945" lims:id="1128945"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128946" lims:id="1128946">Fee — amendment — licence authorizing testing</MarginalNote><Label>47</Label><Text>If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to test drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form, distribute drugs, wholesale drugs or package/label drugs — at that building, the fee for the examination of the application for each building to be added is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128947" lims:id="1128947"><Label>(a)</Label><Text>in respect of drugs for human use,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128948" lims:id="1128948"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 7 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128949" lims:id="1128949"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2); and</Text></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128950" lims:id="1128950"><Label>(b)</Label><Text>in respect of drugs for veterinary use only,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128951" lims:id="1128951"><Label>(i)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 7 for that fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128952" lims:id="1128952"><Label>(ii)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128953" lims:id="1128953"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128954" lims:id="1128954">Prorated fee</MarginalNote><Label>48</Label><Text>The fee that is payable under subsection <XRefInternal>29</XRefInternal>(1) is reduced by the percentage set out in column 1 of Schedule 5 if the person referred to in subsection <XRefInternal>29</XRefInternal>(2) files, in the period set out in column 2,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128955" lims:id="1128955"><Label>(a)</Label><Text>an application for an establishment licence and has not previously filed such an application; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128956" lims:id="1128956"><Label>(b)</Label><Text>an application to amend an establishment licence that seeks to add a building.</Text></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128957" lims:id="1128957"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128958" lims:id="1128958">Remission — small business</MarginalNote><Label>49</Label><Text>Subject to section <XRefInternal>50</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>29</XRefInternal>(2) of an amount equal to 25% of the fee that is payable under subsection <XRefInternal>29</XRefInternal>(1) if the person provides with their application, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128959" lims:id="1128959"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128960" lims:id="1128960"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128961" lims:id="1128961"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128962" lims:id="1128962"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128963" lims:id="1128963"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128964" lims:id="1128964"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128965" lims:id="1128965"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128966" lims:id="1128966"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128967" lims:id="1128967"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128968" lims:id="1128968"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128969" lims:id="1128969"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128970" lims:id="1128970"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128971" lims:id="1128971"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128972" lims:id="1128972"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128973" lims:id="1128973"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128974" lims:id="1128974">Difference payable</MarginalNote><Label>50</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>29</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>29</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128975" lims:id="1128975"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128976" lims:id="1128976"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128977" lims:id="1128977" level="2"><Label>DIVISION 4</Label><TitleText>Fees for Right to Sell Drugs for Human Use</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128978" lims:id="1128978" level="3"><TitleText>Non-application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128979" lims:id="1128979"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128980" lims:id="1128980">Non-application</MarginalNote><Label>51</Label><Text>This Division does not apply to drugs for veterinary use only.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1128981" lims:id="1128981" level="3"><TitleText>Fees and Remission</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128982" lims:id="1128982"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128983" lims:id="1128983">Annual fee</MarginalNote><Label>52</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128984" lims:id="1128984"><Label>(1)</Label><Text>The annual fee that is payable for the right to sell a drug for which a drug identification number has been assigned under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> is, in respect of the type of drug set out in column 1 of Schedule 6, as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128985" lims:id="1128985"><Label>(a)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 6, the fee set out in that column; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128986" lims:id="1128986"><Label>(b)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 6, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128987" lims:id="1128987"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128988" lims:id="1128988">Fee payable by person after first sale</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person to which a document was issued under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> that sets out the drug identification number assigned for the drug if the person has sold the drug following the issuance of the document.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128989" lims:id="1128989"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128990" lims:id="1128990">Timing of payment</MarginalNote><Label>(3)</Label><Text>The fee is payable on October 1.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128991" lims:id="1128991"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128992" lims:id="1128992">Non-application — interruption of sale</MarginalNote><Label>(4)</Label><Text>Subject to subsection (5), subsection (1) does not apply to the person if they notified the Minister in accordance with section C.01.014.71 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> in the 12 months preceding October 1.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128993" lims:id="1128993"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128994" lims:id="1128994">Resumption of sale</MarginalNote><Label>(5)</Label><Text>Subsection (4) ceases to apply on the day on which the person notifies the Minister in accordance with section C.01.014.72 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1128995" lims:id="1128995"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128996" lims:id="1128996">Remission — small business</MarginalNote><Label>53</Label><Text>Subject to section <XRefInternal>54</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>52</XRefInternal>(2) of an amount equal to 25% of the fee that is payable under subsection <XRefInternal>52</XRefInternal>(1) if the person provides with the notification provided under subsection C.01.014.5(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128997" lims:id="1128997"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128998" lims:id="1128998"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1128999" lims:id="1128999"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129000" lims:id="1129000"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129001" lims:id="1129001"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129002" lims:id="1129002"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129003" lims:id="1129003"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129004" lims:id="1129004"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129005" lims:id="1129005"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129006" lims:id="1129006"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129007" lims:id="1129007"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129008" lims:id="1129008"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129009" lims:id="1129009"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129010" lims:id="1129010"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129011" lims:id="1129011"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129012" lims:id="1129012">Difference payable</MarginalNote><Label>54</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>52</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>52</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129013" lims:id="1129013"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129014" lims:id="1129014"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129015" lims:id="1129015" level="2"><Label>DIVISION 5</Label><TitleText>Fees for Right to Sell Drugs for Veterinary Use Only</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129016" lims:id="1129016" level="3"><TitleText>Application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129017" lims:id="1129017"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129018" lims:id="1129018">Application</MarginalNote><Label>55</Label><Text>This Division applies to drug for veterinary use only.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129019" lims:id="1129019" level="3"><TitleText>Fees and Remission</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129020" lims:id="1129020"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129021" lims:id="1129021">Annual fee</MarginalNote><Label>56</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129022" lims:id="1129022"><Label>(1)</Label><Text>The annual fee that is payable for the right to sell a drug for which a drug identification number has been assigned under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> is as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129023" lims:id="1129023"><Label>(a)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 1 to 4 of Schedule 7, the fee set out in that column; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129024" lims:id="1129024"><Label>(b)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 1 to 4 of Schedule 7, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129025" lims:id="1129025"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129026" lims:id="1129026">Fee payable by person after first sale</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person to which a document was issued under subsection C.01.014.2(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> that sets out the drug identification number assigned for the drug if the person has sold the drug following the issuance of the document.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129027" lims:id="1129027"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129028" lims:id="1129028">Timing of payment</MarginalNote><Label>(3)</Label><Text>The fee is payable on October 1.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129029" lims:id="1129029"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129030" lims:id="1129030">Non-application — interruption of sale</MarginalNote><Label>(4)</Label><Text>Subject to subsection (5), subsection (1) does not apply to the person if they notified the Minister in accordance with section C.01.014.71 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> in the 12 months preceding October 1.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129031" lims:id="1129031"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129032" lims:id="1129032">Resumption of sale</MarginalNote><Label>(5)</Label><Text>Subsection (4) ceases to apply on the day on which the person notifies the Minister in accordance with section C.01.014.72 of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129033" lims:id="1129033"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129034" lims:id="1129034">Remission — small business</MarginalNote><Label>57</Label><Text>Subject to section <XRefInternal>58</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>56</XRefInternal>(2) of an amount equal to 25% of the fee that is payable under subsection <XRefInternal>56</XRefInternal>(1) if the person provides with the notification provided under subsection C.01.014.5(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129035" lims:id="1129035"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129036" lims:id="1129036"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129037" lims:id="1129037"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129038" lims:id="1129038"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129039" lims:id="1129039"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129040" lims:id="1129040"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129041" lims:id="1129041"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129042" lims:id="1129042"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129043" lims:id="1129043"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129044" lims:id="1129044"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129045" lims:id="1129045"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129046" lims:id="1129046"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129047" lims:id="1129047"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129048" lims:id="1129048"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129049" lims:id="1129049"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129050" lims:id="1129050">Difference payable</MarginalNote><Label>58</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>56</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>56</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129051" lims:id="1129051"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129052" lims:id="1129052"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531413" lims:id="1531413" level="2"><Label>DIVISION 6</Label><TitleText>Fees for Right to Sell Biocides</TitleText></Heading><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531414" lims:id="1531414"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531415" lims:id="1531415">Annual fee</MarginalNote><Label>58.1</Label><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531416" lims:id="1531416"><Label>(1)</Label><Text>The annual fee that is payable for the right to sell a biocide for which a market authorization has been issued under section 11 of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal> is $1,535.</Text></Subsection><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531417" lims:id="1531417"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531418" lims:id="1531418">Fee payable by person that sold biocide</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person to which a market authorization was issued if the person has sold the biocide in the 12 months preceding October 1.</Text></Subsection><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531419" lims:id="1531419"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531420" lims:id="1531420">Timing of payment</MarginalNote><Label>(3)</Label><Text>The fee is payable on October 1.</Text></Subsection><Subsection lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531421" lims:id="1531421"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531422" lims:id="1531422">Non-application — permanent discontinuance of sale</MarginalNote><Label>(4)</Label><Text>Subsection (1) does not apply to the person if they have informed the Minister, in accordance with section 47 of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>, that they permanently discontinued the sale of the biocide in Canada in the 12 months preceding October 1.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531424" lims:id="1531424" lims:enactId="1456189">SOR/2024-121, s. 7</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531425" lims:id="1531425"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531426" lims:id="1531426">Remission — small business</MarginalNote><Label>58.2</Label><Text>Subject to section <XRefInternal>58.3</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>58.1</XRefInternal>(2) of an amount equal to 25% of the fee that is payable under subsection <XRefInternal>58.1</XRefInternal>(1) if the person provides, with the information referred to in section 46 of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531427" lims:id="1531427"><Label>a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531428" lims:id="1531428"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531429" lims:id="1531429"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531430" lims:id="1531430"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531431" lims:id="1531431"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531432" lims:id="1531432"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531433" lims:id="1531433"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and the gross revenue of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531434" lims:id="1531434"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531435" lims:id="1531435"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531436" lims:id="1531436"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531437" lims:id="1531437"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531438" lims:id="1531438"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531439" lims:id="1531439"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531440" lims:id="1531440"><Label>(D)</Label><Text>the person’s projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531442" lims:id="1531442" lims:enactId="1456189">SOR/2024-121, s. 7</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531443" lims:id="1531443"><MarginalNote lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531444" lims:id="1531444">Difference payable</MarginalNote><Label>58.3</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>58.1</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>58.1</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531445" lims:id="1531445"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <XRefExternal reference-type="regulation">small business</XRefExternal> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531446" lims:id="1531446"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year, but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531448" lims:id="1531448" lims:enactId="1456189">SOR/2024-121, s. 7</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129053" lims:id="1129053" level="1"><Label>PART 3</Label><TitleText>Medical Devices</TitleText></Heading><Heading lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1129054" lims:id="1391052" level="2"><Label>DIVISION 1</Label><TitleText>Fees for Examination of an Application for a Licence, an Amendment Application for a Licence or an Application to Amend an Authorization — Medical Device</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129055" lims:id="1129055" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:lastAmendedDate="2024-01-03" lims:fid="1129056" lims:id="1391044"><MarginalNote lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391045" lims:id="1391045">Definitions</MarginalNote><Label>59</Label><Text>The following definitions apply in this Division.</Text><Definition lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391046" lims:id="1391046"><Text lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1435051" lims:id="1436525"><DefinedTermEn>authorization</DefinedTermEn> means an authorization for a medical device issued under section 68.12 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, if the device</Text><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391047" lims:id="1391047"><Label>(a)</Label><Text>is a Class II, III or IV device; and</Text></Paragraph><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391048" lims:id="1391048"><Label>(b)</Label><Text>is not a UPHN medical device. (<DefinedTermFr>autorisation</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391049" lims:id="1391049"><Text><DefinedTermEn>licence</DefinedTermEn> means a medical device licence issued under paragraph 36(1)(a) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>. (<DefinedTermFr>homologation</DefinedTermFr>)</Text></Definition><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391051" lims:id="1391051" lims:enactId="1390959">SOR/2023-21, s. 4</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436526" lims:id="1436526" lims:enactId="1435007">SOR/2023-278, s. 2</HistoricalNoteSubItem></HistoricalNote></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129058" lims:id="1129058" level="3"><TitleText>Fees and Remissions</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2024-01-03" lims:fid="1129059" lims:id="1129059"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129060" lims:id="1129060">Fee for examination</MarginalNote><Label>60</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129061" lims:id="1129061"><Label>(1)</Label><Text lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1390988" lims:id="1391053">Subject to paragraph 62(b) and section 64, the fee for the examination of an application for a licence that is filed under section 32 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, an application for a licence amendment that is filed under section 34 or an application to amend an authorization filed under section 68.14 of those Regulations is, in respect of the applicable category set out in column 1 of Schedule 8 and described in column 2, as follows:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129062" lims:id="1129062"><Label>(a)</Label><Text>in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 6 of Schedule 8, the fee set out in that column; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129063" lims:id="1129063"><Label>(b)</Label><Text>in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 6 of Schedule 8, the amount that is calculated in accordance with subsection <XRefInternal>4</XRefInternal>(2).</Text></Paragraph></Subsection><Subsection lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436527" lims:id="1436527"><MarginalNote lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436528" lims:id="1436528">Exception</MarginalNote><Label>(1.1)</Label><Text>Subsection (1) does not apply in respect of an application to amend an authorization for a medical device if the purpose of the application is to authorize the device in relation to a medical condition that qualified it as a UPHN medical device when the application was submitted.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129064" lims:id="1129064"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129065" lims:id="1129065">Fee payable by person that files application</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the application.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391055" lims:id="1391055" lims:enactId="1390961">SOR/2023-21, s. 5</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436529" lims:id="1436529" lims:enactId="1435009">SOR/2023-278, s. 3</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129066" lims:id="1129066"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129067" lims:id="1129067">Reinstatement</MarginalNote><Label>61</Label><Text>Every provision of this Division that applies to an application for a licence for a Class II, III or IV medical device filed under section 32 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129068" lims:id="1129068"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129069" lims:id="1129069">Fee and timing of payment — preliminary examination</MarginalNote><Label>62</Label><Text>If a preliminary examination is conducted in respect of an application,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129070" lims:id="1129070"><Label>(a)</Label><Text>the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) stating that the application has been found to be complete and has been accepted for further examination; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129071" lims:id="1129071"><Label>(b)</Label><Text>10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) stating that the application has been found to be incomplete.</Text></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129072" lims:id="1129072"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129073" lims:id="1129073">Fee and timing of payment — no preliminary examination</MarginalNote><Label>63</Label><Text>If a preliminary examination is not conducted in respect of an application, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) stating that the application has been received.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129074" lims:id="1129074"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129075" lims:id="1129075">Fee — filing in previous fiscal year</MarginalNote><Label>64</Label><Text>For the purposes of subsection <XRefInternal>60</XRefInternal>(1), if the Minister issues a notice referred to in section <XRefInternal>62</XRefInternal> or <XRefInternal>63</XRefInternal> in the fiscal year that follows the fiscal year in which the application was filed, the fee that is payable is the fee that was payable in the fiscal year in which the application was filed.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129076" lims:id="1129076"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129077" lims:id="1129077">Remission — General Council Decision</MarginalNote><Label>65</Label><Text>Remission is granted to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) of an amount equal to the fee that is payable under subsection <XRefInternal>60</XRefInternal>(1) if the person has received an authorization under section 21.04 of the <XRefExternal reference-type="act" link="P-4">Patent Act</XRefExternal> in respect of the medical device.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129078" lims:id="1129078"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129079" lims:id="1129079">Remission — small business</MarginalNote><Label>66</Label><Text>Subject to section <XRefInternal>68</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) of an amount equal to 50% of the fee that is payable under subsection <XRefInternal>60</XRefInternal>(1) if the person provides with their application, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129080" lims:id="1129080"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129081" lims:id="1129081"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129082" lims:id="1129082"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129083" lims:id="1129083"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129084" lims:id="1129084"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129085" lims:id="1129085"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129086" lims:id="1129086"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129087" lims:id="1129087"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129088" lims:id="1129088"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129089" lims:id="1129089"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129090" lims:id="1129090"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129091" lims:id="1129091"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129092" lims:id="1129092"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129093" lims:id="1129093"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129094" lims:id="1129094"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129095" lims:id="1129095">Remission — first application by small business</MarginalNote><Label>67</Label><Text>Subject to section <XRefInternal>68</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>60</XRefInternal>(2) of an amount equal to the fee that is payable under subsection <XRefInternal>60</XRefInternal>(1) if the following conditions are met:</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129096" lims:id="1129096"><Label>(a)</Label><Text>the person has not previously filed an application for a licence under section 32 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>; and</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129097" lims:id="1129097"><Label>(b)</Label><Text>the person provides with their application, in a form established by the Minister,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129098" lims:id="1129098"><Label>(i)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129099" lims:id="1129099"><Label>(A)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129100" lims:id="1129100"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129101" lims:id="1129101"><Label>(I)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129102" lims:id="1129102"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129103" lims:id="1129103"><Label>(III)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129104" lims:id="1129104"><Label>(IV)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Subclause></Clause></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129105" lims:id="1129105"><Label>(ii)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129106" lims:id="1129106"><Label>(A)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection 1(1) in their first fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129107" lims:id="1129107"><Label>(B)</Label><Text>the following information:</Text><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129108" lims:id="1129108"><Label>(I)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129109" lims:id="1129109"><Label>(II)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129110" lims:id="1129110"><Label>(III)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Subclause><Subclause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129111" lims:id="1129111"><Label>(IV)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Subclause></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129112" lims:id="1129112"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129113" lims:id="1129113">Fee or difference payable</MarginalNote><Label>68</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>60</XRefInternal>(2) provide additional information, the fee — or the difference between the fee payable under subsection <XRefInternal>60</XRefInternal>(1) and the amount already paid, as the case may be — is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129114" lims:id="1129114"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129115" lims:id="1129115"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129116" lims:id="1129116" level="2"><Label>DIVISION 2</Label><TitleText>Fees for Examination of an Application for an Establishment Licence — Medical Devices</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129117" lims:id="1129117" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129118" lims:id="1129118"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129119" lims:id="1129119">Definition of <DefinitionRef>establishment licence</DefinitionRef></MarginalNote><Label>69</Label><Text>In this Division, <DefinedTermEn>establishment licence</DefinedTermEn> means a licence issued under section 46 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129120" lims:id="1129120" level="3"><TitleText>Application</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129121" lims:id="1129121"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129122" lims:id="1129122">Applicable classes</MarginalNote><Label>70</Label><Text>This Division applies to persons that import or sell medical devices that are subject to the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, other than persons that import or sell only medical devices that are subject to Part 2 or 3 of those Regulations.</Text></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129123" lims:id="1129123" level="3"><TitleText>Fee and Remission</TitleText></Heading><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129124" lims:id="1129124"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129125" lims:id="1129125">Fee for examination</MarginalNote><Label>71</Label><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129126" lims:id="1129126"><Label>(1)</Label><Text>The fee that is payable for the examination of an application for an establishment licence filed under section 45 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> or for the annual review of such a licence filed under section 46.1 of those Regulations is $4,590.</Text></Subsection><Subsection lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129127" lims:id="1129127"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129128" lims:id="1129128">Fee paid by person that files application</MarginalNote><Label>(2)</Label><Text>The fee is payable by the person that files the application.</Text></Subsection></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129129" lims:id="1129129"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129130" lims:id="1129130">Timing of payment</MarginalNote><Label>72</Label><Text>The fee is payable on the issuance by the Minister of a notice to the person referred to in subsection <XRefInternal>71</XRefInternal>(2) stating that the application has been accepted for further examination.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129131" lims:id="1129131"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129132" lims:id="1129132">Reinstatement</MarginalNote><Label>73</Label><Text>Every provision of this Division that applies to an application for an establishment licence also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129133" lims:id="1129133"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129134" lims:id="1129134">Remission — small business</MarginalNote><Label>74</Label><Text>Subject to section <XRefInternal>75</XRefInternal>, remission is granted to the person referred to in subsection <XRefInternal>71</XRefInternal>(2) of an amount equal to 25% of the fee that is payable under subsection <XRefInternal>71</XRefInternal>(1) if the person provides with their application, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129135" lims:id="1129135"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129136" lims:id="1129136"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129137" lims:id="1129137"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129138" lims:id="1129138"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129139" lims:id="1129139"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129140" lims:id="1129140"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129141" lims:id="1129141"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129142" lims:id="1129142"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129143" lims:id="1129143"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129144" lims:id="1129144"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129145" lims:id="1129145"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129146" lims:id="1129146"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129147" lims:id="1129147"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129148" lims:id="1129148"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129149" lims:id="1129149"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129150" lims:id="1129150">Difference payable</MarginalNote><Label>75</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>71</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>71</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129151" lims:id="1129151"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129152" lims:id="1129152"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1129153" lims:id="1391065" level="2"><Label>DIVISION 3</Label><TitleText>Fees for Right to Sell Licensed or Authorized Class II, III or IV Medical Devices</TitleText></Heading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129154" lims:id="1129154" level="3"><TitleText>Interpretation</TitleText></Heading><Section lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:lastAmendedDate="2024-01-03" lims:fid="1129155" lims:id="1391056"><MarginalNote lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391057" lims:id="1391057">Definitions</MarginalNote><Label>76</Label><Text>The following definitions apply in this Division.</Text><Definition lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391058" lims:id="1391058"><Text lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1435052" lims:id="1436530"><DefinedTermEn>authorization</DefinedTermEn> means an authorization for a medical device issued under section 68.12 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, if the device</Text><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391059" lims:id="1391059"><Label>(a)</Label><Text>is a Class II, III or IV device; and</Text></Paragraph><Paragraph lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391060" lims:id="1391060"><Label>(b)</Label><Text>is not a UPHN medical device. (<DefinedTermFr>autorisation</DefinedTermFr>)</Text></Paragraph></Definition><Definition lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391061" lims:id="1391061"><Text><DefinedTermEn>licence</DefinedTermEn> means a medical device licence issued under paragraph 36(1)(a) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>. (<DefinedTermFr>homologation</DefinedTermFr>)</Text></Definition><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391063" lims:id="1391063" lims:enactId="1390963">SOR/2023-21, s. 6</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436531" lims:id="1436531" lims:enactId="1435011">SOR/2023-278, s. 4</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:lastAmendedDate="2024-01-03" lims:fid="1129158" lims:id="1391066"><MarginalNote lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391067" lims:id="1391067">Annual fee</MarginalNote><Label>77</Label><Subsection lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1391068" lims:id="1436537"><Label>(1)</Label><Text>The annual fee that is payable for the right to sell a licensed Class II, III or IV medical device or an authorized Class II, III or IV medical device that is not a UPHN medical device is $381.</Text></Subsection><Subsection lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391069" lims:id="1391069"><MarginalNote lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391070" lims:id="1391070">Fee payable by holder</MarginalNote><Label>(2)</Label><Text>The fee is payable either by the person that holds the licence for the Class II, III or IV medical device, if the licence is not suspended under section 40 or 41 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, or by the person that holds the authorization.</Text></Subsection><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391072" lims:id="1391072" lims:enactId="1390963">SOR/2023-21, s. 6</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436536" lims:id="1436536" lims:enactId="1435015">SOR/2023-278, s. 6</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129163" lims:id="1129163"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129164" lims:id="1129164">Timing of payment</MarginalNote><Label>78</Label><Text>The fee is payable on December 20.</Text></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2023-02-22" lims:fid="1129165" lims:id="1129165"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129166" lims:id="1129166">Remission — small business</MarginalNote><Label>79</Label><Text lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1390989" lims:id="1391073">Subject to section 80, remission is granted to the person referred to in subsection 77(2) of an amount equal to 25% of the fee that is payable under subsection 77(1) if the person provides the Minister with the statement provided under subsection 43(1) or section 68.24 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal>, in a form established by the Minister,</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129167" lims:id="1129167"><Label>(a)</Label><Text>in the case where the person has completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129168" lims:id="1129168"><Label>(i)</Label><Text>a statement indicating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their last completed fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129169" lims:id="1129169"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129170" lims:id="1129170"><Label>(A)</Label><Text>a list of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129171" lims:id="1129171"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129172" lims:id="1129172"><Label>(C)</Label><Text>the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129173" lims:id="1129173"><Label>(D)</Label><Text>the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and</Text></Clause></Subparagraph></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129174" lims:id="1129174"><Label>(b)</Label><Text>in the case where the person has not completed their first fiscal year,</Text><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129175" lims:id="1129175"><Label>(i)</Label><Text>a statement indicating that the person anticipates meeting the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in their first fiscal year, and</Text></Subparagraph><Subparagraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129176" lims:id="1129176"><Label>(ii)</Label><Text>the following information:</Text><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129177" lims:id="1129177"><Label>(A)</Label><Text>a list of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129178" lims:id="1129178"><Label>(B)</Label><Text>the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129179" lims:id="1129179"><Label>(C)</Label><Text>the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and</Text></Clause><Clause lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129180" lims:id="1129180"><Label>(D)</Label><Text>the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.</Text></Clause></Subparagraph></Paragraph><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391075" lims:id="1391075" lims:enactId="1390965">SOR/2023-21, s. 7</HistoricalNoteSubItem></HistoricalNote></Section><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129181" lims:id="1129181"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129182" lims:id="1129182">Difference payable</MarginalNote><Label>80</Label><Text>If the Minister requests under section <XRefInternal>5</XRefInternal> that the person referred to in subsection <XRefInternal>77</XRefInternal>(2) provide additional information, the difference between the fee payable under subsection <XRefInternal>77</XRefInternal>(1) and the amount already paid is immediately payable if</Text><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129183" lims:id="1129183"><Label>(a)</Label><Text>the person has not provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition <DefinitionRef>small business</DefinitionRef> in subsection <XRefInternal>1</XRefInternal>(1) in the applicable fiscal year; or</Text></Paragraph><Paragraph lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129184" lims:id="1129184"><Label>(b)</Label><Text>the person has provided, within the period specified in section <XRefInternal>5</XRefInternal>, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.</Text></Paragraph></Section><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129185" lims:id="1129185" level="1"><TitleText>Coming into Force</TitleText></Heading><Section lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2019-05-08" lims:fid="1129186" lims:id="1129186" type="CIFnobold"><MarginalNote lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129187" lims:id="1129187">SOR/96-143</MarginalNote><Label><FootnoteRef idref="fn_SOR-2019-124_e_transform_hq_25134">*</FootnoteRef>81</Label><Text>This Order comes into force on the day on which the <XRefExternal reference-type="regulation" link="SOR-96-143">Veterinary Drug Evaluation Fees Regulations</XRefExternal> are repealed but if it is registered after that day, it comes into force on the day on which it is registered.</Text><Footnote id="fn_SOR-2019-124_e_transform_hq_25134" placement="section" status="official"><Label>*</Label><Text>[Note: Regulations in force April 1, 2020.]</Text></Footnote></Section></Body><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2021-03-19" lims:fid="1129188" lims:id="1129188" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129189" lims:id="1129189"><Label>SCHEDULE 1</Label><OriginatingRef>(Section <XRefInternal>9</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129190" lims:id="1129190" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129191" lims:id="1129191" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129192" lims:id="1129192">Fees for Examination of a Submission — Drugs for Human Use</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129193" lims:id="1129193" cols="7"><colspec colname="COLSPEC17" colwidth="143.62*" /><colspec colname="2" colwidth="415.09*" /><colspec colname="COLSPEC1" colwidth="921.91*" /><colspec colname="COLSPEC11" colwidth="301.20*" /><colspec colname="COLSPEC10" colwidth="299.40*" /><colspec colname="COLSPEC9" colwidth="295.82*" /><colspec char="" colname="3" colwidth="272.48*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129194" lims:id="1129194"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 3</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 4</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 5</entry><entry colsep="0" rowsep="0" valign="top">Column 6</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Submission Class</entry><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Description</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry char="." colsep="0" valign="bottom">2020-2021</entry><entry char="." colsep="0" valign="bottom">2021-2022</entry><entry char="." colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129195" lims:id="1129195"><row lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289270" lims:id="1289587"><entry colsep="0" rowsep="0">1</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">New active substance</entry><entry colsep="0" rowsep="0">Submissions in support of a drug, other than a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph<FootnoteRef idref="newfootnote_1">1</FootnoteRef></entry><entry char="." colsep="0" rowsep="0" valign="bottom">400,288</entry><entry char="." colsep="0" rowsep="0" valign="bottom">437,884</entry><entry char="." colsep="0" rowsep="0" valign="bottom">475,481</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">513,077</entry></row><row><entry colsep="0" rowsep="0">2</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Clinical or non-clinical data and chemistry and manufacturing data</entry><entry colsep="0" rowsep="0">Submissions based on clinical or non-clinical data and chemistry and manufacturing data for a drug that does not include a new active substance</entry><entry char="." colsep="0" rowsep="0" valign="bottom">204,197</entry><entry char="." colsep="0" rowsep="0" valign="bottom">224,691</entry><entry char="." colsep="0" rowsep="0" valign="bottom">245,185</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">265,678</entry></row><row><entry colsep="0" rowsep="0">3</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Clinical or non-clinical data only</entry><entry colsep="0" rowsep="0">Submissions based only on clinical or non-clinical data for a drug that does not include a new active substance</entry><entry char="." colsep="0" rowsep="0" valign="bottom">90,864</entry><entry char="." colsep="0" rowsep="0" valign="bottom">95,987</entry><entry char="." colsep="0" rowsep="0" valign="bottom">101,110</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">106,232</entry></row><row><entry colsep="0" rowsep="0">4</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Comparative studies</entry><entry colsep="0" rowsep="0">Submissions based on comparative studies (e.g., clinical or non-clinical data, bioavailability data and data on the pharmacokinetics and pharmacodynamics of the drug) with or without chemistry and manufacturing data for a drug that does not include a new active substance</entry><entry char="." colsep="0" rowsep="0" valign="bottom">53,836</entry><entry char="." colsep="0" rowsep="0" valign="bottom">55,848</entry><entry char="." colsep="0" rowsep="0" valign="bottom">57,859</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">59,870</entry></row><row><entry colsep="0" rowsep="0">5</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Chemistry and manufacturing data only</entry><entry colsep="0" rowsep="0">Submissions based only on chemistry and manufacturing data for a drug that does not include a new active substance</entry><entry char="." colsep="0" rowsep="0" valign="bottom">27,587</entry><entry char="." colsep="0" rowsep="0" valign="bottom">30,670</entry><entry char="." colsep="0" rowsep="0" valign="bottom">33,752</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">36,835</entry></row><row><entry colsep="0" rowsep="0">6</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Clinical or non-clinical data only, in support of safety updates to the labelling</entry><entry colsep="0" rowsep="0">Submissions based only on clinical or non-clinical data, in support of safety updates to the labelling materials for a new drug that does not include a new active substance</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,442</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,442</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,442</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">19,442</entry></row><row><entry colsep="0" rowsep="0">7</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Labelling only</entry><entry colsep="0" rowsep="0">Submissions, other than those described in item 8, 11 or 12, of labelling material, that include data in support of the following: brand name assessment, standardized or published test methods, in vitro or in vivo photostability or applications for a drug identification number in support of changes to brand names of non-prescription drugs (but not including examination of other supporting clinical or non-clinical data, comparative data, or chemistry and manufacturing data)</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,816</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,328</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,841</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">5,353</entry></row><row><entry colsep="0" rowsep="0">8</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0">Labelling only (generic drugs)</entry><entry colsep="0" rowsep="0">Submissions in support of a change to the labelling to be consistent with the Canadian reference product that do not include any additional labelling updates requiring a labelling assessment</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,010</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,010</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,010</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">2,010</entry></row><row><entry colsep="0" rowsep="0">9</entry><entry colsep="0" rowheader="yes" rowsep="0">Administrative submission</entry><entry colsep="0" rowsep="0">Submissions in support of a change in the manufacturer’s name or brand name, including the following: changes in ownership of the drug, request for an additional brand name or changes resulting from a licensing agreement being entered into by two manufacturers that do not require an assessment of labelling material or brand name (e.g., post-authorization label changes filed by licensees to remain identical to licensor’s drug and post-authorization chemistry and manufacturing updates for drugs listed in Schedule C or D of the <XRefExternal reference-type="act" link="F-27">Food and Drugs Act</XRefExternal>)</entry><entry char="." colsep="0" rowsep="0" valign="bottom">432</entry><entry char="." colsep="0" rowsep="0" valign="bottom">540</entry><entry char="." colsep="0" rowsep="0" valign="bottom">676</entry><entry colsep="0" rowsep="0" valign="bottom">845</entry></row><row lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1457313" lims:id="1457313"><entry colsep="0" rowsep="0">10</entry><entry colsep="0" rowheader="yes" rowsep="0">Disinfectant — full review</entry><entry colsep="0" rowsep="0">Submissions, other than those described in item 11, that include data in support of a disinfectant</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,712</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,140</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,925</entry><entry colsep="0" rowsep="0" valign="bottom">11,157</entry></row><row lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1457314" lims:id="1457314"><entry colsep="0" rowsep="0">11</entry><entry colsep="0" rowheader="yes" rowsep="0">Labelling only (disinfectants)</entry><entry colsep="0" rowsep="0">Submissions in support of changes to the labelling of disinfectants that do not require supporting data, submissions in support of safety updates for disinfectants that are new drugs or submissions in support of a change in the manufacturer’s name or brand name that requires a review of labelling material due to deviations from the previously authorized labelling or drug</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,507</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,507</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,507</entry><entry colsep="0" rowsep="0" valign="bottom">2,507</entry></row><row><entry colsep="0" rowsep="0">12</entry><entry colsep="0" rowheader="yes" rowsep="0">Drug identification number application — labelling standards</entry><entry colsep="0" rowsep="0">Applications, including those that pertain to changes to brand names for non-prescription drugs, that include an attestation of compliance with a labelling standard or Category IV Monograph for a drug and that do not include clinical or non-clinical data or chemistry and manufacturing data</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,616</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,616</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,616</entry><entry colsep="0" rowsep="0" valign="bottom">1,616</entry></row></tbody></tgroup></table><Footnote lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289589" lims:id="1289589" id="newfootnote_1" placement="table" status="official"><Label>1</Label><Text>A medicinal ingredient is not considered to be approved in a drug by reason of the Minister having issued or amended an authorization under the ISAD Interim Order in respect of a COVID-19 drug that contains the medicinal ingredient.</Text></Footnote></TableGroup><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289591" lims:id="1289591" lims:enactId="1289170">SOR/2021-47, s. 4</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2021-03-19" lims:enacted-date="2021-03-19" lims:fid="1289592" lims:id="1289592" lims:enactId="1289172">SOR/2021-47, s. 5</HistoricalNoteSubItem></HistoricalNote></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129196" lims:id="1129196" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129197" lims:id="1129197"><Label>SCHEDULE 2</Label><OriginatingRef>(Section <XRefInternal>21</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129198" lims:id="1129198" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129199" lims:id="1129199" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129200" lims:id="1129200">Fees for Examination of a Submission — Drugs for Veterinary Use Only</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129201" lims:id="1129201" cols="10"><colspec colname="COLSPEC2" colwidth="27.76pt" /><colspec colname="2" colwidth="266.74*" /><colspec colname="COLSPEC1" colwidth="459.57*" /><colspec colname="COLSPEC4" colwidth="131.34*" /><colspec colname="COLSPEC5" colwidth="129.92*" /><colspec colname="COLSPEC6" colwidth="131.34*" /><colspec colname="COLSPEC8" colwidth="129.92*" /><colspec colname="COLSPEC7" colwidth="129.92*" /><colspec colname="COLSPEC3" colwidth="129.92*" /><colspec align="left" char="." charoff="50" colname="3" colwidth="131.34*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129202" lims:id="1129202"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 3</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 4</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 5</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 6</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 7</entry><entry char="." colsep="0" rowsep="0" valign="top">Column 8</entry><entry colsep="0" rowsep="0" valign="top">Column 9</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Type of Submission</entry><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Component</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry char="." colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry char="." colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry char="." colsep="0" valign="bottom">2020-2021</entry><entry char="." colsep="0" valign="bottom">2021-2022</entry><entry char="." colsep="0" valign="bottom">2022-2023</entry><entry char="." colsep="0" valign="bottom">2023-2024</entry><entry char="." colsep="0" valign="bottom">2024-2025</entry><entry char="." colsep="0" valign="bottom">2025-2026</entry><entry colsep="0" rowsep="1" valign="bottom">2026-2027</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129203" lims:id="1129203"><row><entry colsep="0" rowsep="0">1</entry><entry colsep="0" rowheader="yes" rowsep="0">Application for drug identification number</entry><entry colsep="0" rowsep="0">Information, other than that referred to in item 2, to support an application for a drug identification number, including the submission of labelling material for a second review, if required</entry><entry char="." colsep="0" rowsep="0" valign="bottom">918</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,148</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,436</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,714</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,959</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,204</entry><entry colsep="0" rowsep="0" valign="bottom">2,448</entry></row><row><entry colsep="0" rowsep="0">2</entry><entry colsep="0" rowheader="yes" rowsep="0">Application for drug identification number</entry><entry colsep="0" rowsep="0">Published references or other data</entry><entry char="." colsep="0" rowsep="0" valign="bottom">638</entry><entry char="." colsep="0" rowsep="0" valign="bottom">798</entry><entry char="." colsep="0" rowsep="0" valign="bottom">998</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,191</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,361</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,532</entry><entry colsep="0" rowsep="0" valign="bottom">1,701</entry></row><row><entry colsep="0" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Application for drug identification number</entry><entry colsep="0" rowsep="0">Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug<FootnoteRef idref="fn_1">1</FootnoteRef></entry><entry char="." colsep="0" rowsep="0" valign="bottom">320</entry><entry char="." colsep="0" rowsep="0" valign="bottom">400</entry><entry char="." colsep="0" rowsep="0" valign="bottom">500</entry><entry char="." colsep="0" rowsep="0" valign="bottom">596</entry><entry char="." colsep="0" rowsep="0" valign="bottom">681</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry colsep="0" rowsep="0" valign="bottom">850</entry></row><row><entry colsep="0" rowsep="0">4</entry><entry colsep="0" rowheader="yes" rowsep="0">Notification — veterinary health product</entry><entry colsep="0" rowsep="0">Information contained in a notification filed under subsection C.01.615(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal> in respect of a veterinary health product</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry char="." colsep="0" rowsep="0" valign="bottom">486</entry><entry colsep="0" rowsep="0" valign="bottom">486</entry></row><row><entry colsep="0" rowsep="0">5</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species)</entry><entry char="." colsep="0" rowsep="0" valign="bottom">20,375</entry><entry char="." colsep="0" rowsep="0" valign="bottom">25,469</entry><entry char="." colsep="0" rowsep="0" valign="bottom">31,837</entry><entry char="." colsep="0" rowsep="0" valign="bottom">38,033</entry><entry char="." colsep="0" rowsep="0" valign="bottom">43,467</entry><entry char="." colsep="0" rowsep="0" valign="bottom">48,900</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">54,333</entry></row><row><entry colsep="0" rowsep="0">6</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">12,342</entry><entry char="." colsep="0" rowsep="0" valign="bottom">15,428</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,286</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,039</entry><entry char="." colsep="0" rowsep="0" valign="bottom">26,331</entry><entry char="." colsep="0" rowsep="0" valign="bottom">29,622</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">32,913</entry></row><row><entry colsep="0" rowsep="0">7</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">29,631</entry><entry char="." colsep="0" rowsep="0" valign="bottom">37,040</entry><entry char="." colsep="0" rowsep="0" valign="bottom">46,300</entry><entry char="." colsep="0" rowsep="0" valign="bottom">55,312</entry><entry char="." colsep="0" rowsep="0" valign="bottom">63,214</entry><entry char="." colsep="0" rowsep="0" valign="bottom">71,116</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">79,017</entry></row><row><entry colsep="0" rowsep="0">8</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">40,125</entry><entry char="." colsep="0" rowsep="0" valign="bottom">50,157</entry><entry char="." colsep="0" rowsep="0" valign="bottom">62,697</entry><entry char="." colsep="0" rowsep="0" valign="bottom">74,899</entry><entry char="." colsep="0" rowsep="0" valign="bottom">85,599</entry><entry char="." colsep="0" rowsep="0" valign="bottom">96,299</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">106,998</entry></row><row><entry colsep="0" rowsep="0">9</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">10</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength</entry><entry char="." colsep="0" rowsep="0" valign="bottom">612</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry char="." colsep="0" rowsep="0" valign="bottom">957</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,143</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,306</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,469</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">1,632</entry></row><row><entry colsep="0" rowsep="0">11</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">New drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">27,783</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,729</entry><entry char="." colsep="0" rowsep="0" valign="bottom">43,412</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51,861</entry><entry char="." colsep="0" rowsep="0" valign="bottom">59,270</entry><entry char="." colsep="0" rowsep="0" valign="bottom">66,678</entry><entry colname="3" colsep="0" rowsep="0" valign="bottom">74,086</entry></row><row><entry colsep="0" rowsep="0">12</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">37,040</entry><entry char="." colsep="0" rowsep="0" valign="bottom">46,300</entry><entry char="." colsep="0" rowsep="0" valign="bottom">57,875</entry><entry char="." colsep="0" rowsep="0" valign="bottom">69,140</entry><entry char="." colsep="0" rowsep="0" valign="bottom">79,017</entry><entry char="." colsep="0" rowsep="0" valign="bottom">88,893</entry><entry colsep="0" rowsep="0" valign="bottom">98,770</entry></row><row><entry colsep="0" rowsep="0">13</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">14</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">18,513</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,142</entry><entry char="." colsep="0" rowsep="0" valign="bottom">28,928</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,558</entry><entry char="." colsep="0" rowsep="0" valign="bottom">39,495</entry><entry char="." colsep="0" rowsep="0" valign="bottom">44,432</entry><entry colsep="0" rowsep="0" valign="bottom">49,368</entry></row><row><entry colsep="0" rowsep="0">15</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">16</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support one strength of a single dosage form</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">17</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 16</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,086</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,858</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,823</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,760</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,584</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,407</entry><entry colsep="0" rowsep="0" valign="bottom">8,229</entry></row><row><entry colsep="0" rowsep="0">18</entry><entry colsep="0" rowheader="yes" rowsep="0">New drug submission</entry><entry colsep="0" rowsep="0">Documentation to support a change of manufacturer<FootnoteRef idref="fn_2">2</FootnoteRef></entry><entry char="." colsep="0" rowsep="0" valign="bottom">320</entry><entry char="." colsep="0" rowsep="0" valign="bottom">400</entry><entry char="." colsep="0" rowsep="0" valign="bottom">500</entry><entry char="." colsep="0" rowsep="0" valign="bottom">596</entry><entry char="." colsep="0" rowsep="0" valign="bottom">681</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry colsep="0" rowsep="0" valign="bottom">850</entry></row><row><entry colsep="0" rowsep="0">19</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy data to support an additional indication in one animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">16,053</entry><entry char="." colsep="0" rowsep="0" valign="bottom">20,067</entry><entry char="." colsep="0" rowsep="0" valign="bottom">25,084</entry><entry char="." colsep="0" rowsep="0" valign="bottom">29,965</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,246</entry><entry char="." colsep="0" rowsep="0" valign="bottom">38,527</entry><entry colsep="0" rowsep="0" valign="bottom">42,807</entry></row><row><entry colsep="0" rowsep="0">20</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">12,342</entry><entry char="." colsep="0" rowsep="0" valign="bottom">15,428</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,286</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,039</entry><entry char="." colsep="0" rowsep="0" valign="bottom">26,331</entry><entry char="." colsep="0" rowsep="0" valign="bottom">29,622</entry><entry colsep="0" rowsep="0" valign="bottom">32,913</entry></row><row><entry colsep="0" rowsep="0">21</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support an indication in another animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">20,375</entry><entry char="." colsep="0" rowsep="0" valign="bottom">25,469</entry><entry char="." colsep="0" rowsep="0" valign="bottom">31,837</entry><entry char="." colsep="0" rowsep="0" valign="bottom">38,033</entry><entry char="." colsep="0" rowsep="0" valign="bottom">43,467</entry><entry char="." colsep="0" rowsep="0" valign="bottom">48,900</entry><entry colsep="0" rowsep="0" valign="bottom">54,333</entry></row><row><entry colsep="0" rowsep="0">22</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">29,631</entry><entry char="." colsep="0" rowsep="0" valign="bottom">37,040</entry><entry char="." colsep="0" rowsep="0" valign="bottom">46,300</entry><entry char="." colsep="0" rowsep="0" valign="bottom">55,312</entry><entry char="." colsep="0" rowsep="0" valign="bottom">63,214</entry><entry char="." colsep="0" rowsep="0" valign="bottom">71,116</entry><entry colsep="0" rowsep="0" valign="bottom">79,017</entry></row><row><entry colsep="0" rowsep="0">23</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">40,125</entry><entry char="." colsep="0" rowsep="0" valign="bottom">50,157</entry><entry char="." colsep="0" rowsep="0" valign="bottom">62,697</entry><entry char="." colsep="0" rowsep="0" valign="bottom">74,899</entry><entry char="." colsep="0" rowsep="0" valign="bottom">85,599</entry><entry char="." colsep="0" rowsep="0" valign="bottom">96,299</entry><entry colsep="0" rowsep="0" valign="bottom">106,998</entry></row><row><entry colsep="0" rowsep="0">24</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,869</entry><entry char="." colsep="0" rowsep="0" valign="bottom">12,336</entry><entry char="." colsep="0" rowsep="0" valign="bottom">15,421</entry><entry char="." colsep="0" rowsep="0" valign="bottom">18,422</entry><entry char="." colsep="0" rowsep="0" valign="bottom">21,053</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,685</entry><entry colsep="0" rowsep="0" valign="bottom">26,316</entry></row><row><entry colsep="0" rowsep="0">25</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">26</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength</entry><entry char="." colsep="0" rowsep="0" valign="bottom">612</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry char="." colsep="0" rowsep="0" valign="bottom">957</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,143</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,306</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,469</entry><entry colsep="0" rowsep="0" valign="bottom">1,632</entry></row><row><entry colsep="0" rowsep="0">27</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">28</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">18,513</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,142</entry><entry char="." colsep="0" rowsep="0" valign="bottom">28,928</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,558</entry><entry char="." colsep="0" rowsep="0" valign="bottom">39,495</entry><entry char="." colsep="0" rowsep="0" valign="bottom">44,432</entry><entry colsep="0" rowsep="0" valign="bottom">49,368</entry></row><row><entry colsep="0" rowsep="0">29</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,257</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,571</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,464</entry><entry char="." colsep="0" rowsep="0" valign="bottom">17,279</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,748</entry><entry char="." colsep="0" rowsep="0" valign="bottom">22,216</entry><entry colsep="0" rowsep="0" valign="bottom">24,684</entry></row><row><entry colsep="0" rowsep="0">30</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,409</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,261</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,576</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,829</entry><entry char="." colsep="0" rowsep="0" valign="bottom">15,804</entry><entry char="." colsep="0" rowsep="0" valign="bottom">17,780</entry><entry colsep="0" rowsep="0" valign="bottom">19,755</entry></row><row><entry colsep="0" rowsep="0">31</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">32</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a change in formulation or dosage form</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,086</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,858</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,823</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,760</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,584</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,407</entry><entry colsep="0" rowsep="0" valign="bottom">8,229</entry></row><row><entry colsep="0" rowsep="0">33</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a change in the packaging or sterilization process</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,462</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,078</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,848</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,595</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,250</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,906</entry><entry colsep="0" rowsep="0" valign="bottom">6,562</entry></row><row><entry colsep="0" rowsep="0">34</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support an extension of the expiry date</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,850</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,313</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,891</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,452</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,945</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,437</entry><entry colsep="0" rowsep="0" valign="bottom">4,930</entry></row><row><entry colsep="0" rowsep="0">35</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support the concurrent use of two drugs</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,850</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,313</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,891</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,452</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,945</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,437</entry><entry colsep="0" rowsep="0" valign="bottom">4,930</entry></row><row><entry colsep="0" rowsep="0">36</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form</entry><entry char="." colsep="0" rowsep="0" valign="bottom">612</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry char="." colsep="0" rowsep="0" valign="bottom">957</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,143</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,306</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,469</entry><entry colsep="0" rowsep="0" valign="bottom">1,632</entry></row><row><entry colsep="0" rowsep="0">37</entry><entry colsep="0" rowheader="yes" rowsep="0">Supplement to a new drug submission</entry><entry colsep="0" rowsep="0">Documentation to support a change to the brand name of a drug<FootnoteRef idref="fn_3">3</FootnoteRef></entry><entry char="." colsep="0" rowsep="0" valign="bottom">320</entry><entry char="." colsep="0" rowsep="0" valign="bottom">400</entry><entry char="." colsep="0" rowsep="0" valign="bottom">500</entry><entry char="." colsep="0" rowsep="0" valign="bottom">596</entry><entry char="." colsep="0" rowsep="0" valign="bottom">681</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry colsep="0" rowsep="0" valign="bottom">850</entry></row><row><entry colsep="0" rowsep="0">38</entry><entry colsep="0" rowheader="yes" rowsep="0">Abbreviated new drug submission or supplement to an abbreviated new drug submission</entry><entry colsep="0" rowsep="0">Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">39</entry><entry colsep="0" rowheader="yes" rowsep="0">Abbreviated new drug submission or supplement to an abbreviated new drug submission</entry><entry colsep="0" rowsep="0">For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,698</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,623</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,779</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,903</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,889</entry><entry char="." colsep="0" rowsep="0" valign="bottom">8,876</entry><entry colsep="0" rowsep="0" valign="bottom">9,861</entry></row><row><entry colsep="0" rowsep="0">40</entry><entry colsep="0" rowheader="yes" rowsep="0">Abbreviated new drug submission or supplement to an abbreviated new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">41</entry><entry colsep="0" rowheader="yes" rowsep="0">Abbreviated new drug submission or supplement to an abbreviated new drug submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a single dosage form</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">42</entry><entry colsep="0" rowheader="yes" rowsep="0">Abbreviated new drug submission or supplement to an abbreviated new drug submission</entry><entry colsep="0" rowsep="0"><Provision format-ref="indent-0-0"><Text>Documentation to support</Text><Provision format-ref="indent-1-1"><Label>(a)</Label><Text>a change of manufacturer, in the case of an abbreviated new drug submission; or</Text></Provision><Provision format-ref="indent-1-1"><Label>(b)</Label><Text>a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission<FootnoteRef idref="fn_4">4</FootnoteRef></Text></Provision></Provision></entry><entry char="." colsep="0" rowsep="0" valign="bottom">320</entry><entry char="." colsep="0" rowsep="0" valign="bottom">400</entry><entry char="." colsep="0" rowsep="0" valign="bottom">500</entry><entry char="." colsep="0" rowsep="0" valign="bottom">596</entry><entry char="." colsep="0" rowsep="0" valign="bottom">681</entry><entry char="." colsep="0" rowsep="0" valign="bottom">765</entry><entry colsep="0" rowsep="0" valign="bottom">850</entry></row><row><entry colsep="0" rowsep="0">43</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">44</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,935</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,169</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,712</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,211</entry><entry char="." colsep="0" rowsep="0" valign="bottom">10,527</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,843</entry><entry colsep="0" rowsep="0" valign="bottom">13,158</entry></row><row><entry colsep="0" rowsep="0">45</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">18,513</entry><entry char="." colsep="0" rowsep="0" valign="bottom">23,142</entry><entry char="." colsep="0" rowsep="0" valign="bottom">28,928</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,558</entry><entry char="." colsep="0" rowsep="0" valign="bottom">39,495</entry><entry char="." colsep="0" rowsep="0" valign="bottom">44,432</entry><entry colsep="0" rowsep="0" valign="bottom">49,368</entry></row><row><entry colsep="0" rowsep="0">46</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">27,783</entry><entry char="." colsep="0" rowsep="0" valign="bottom">34,729</entry><entry char="." colsep="0" rowsep="0" valign="bottom">43,412</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51,861</entry><entry char="." colsep="0" rowsep="0" valign="bottom">59,270</entry><entry char="." colsep="0" rowsep="0" valign="bottom">66,678</entry><entry colsep="0" rowsep="0" valign="bottom">74,086</entry></row><row><entry colsep="0" rowsep="0">47</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">37,040</entry><entry char="." colsep="0" rowsep="0" valign="bottom">46,300</entry><entry char="." colsep="0" rowsep="0" valign="bottom">57,875</entry><entry char="." colsep="0" rowsep="0" valign="bottom">69,140</entry><entry char="." colsep="0" rowsep="0" valign="bottom">79,017</entry><entry char="." colsep="0" rowsep="0" valign="bottom">88,893</entry><entry colsep="0" rowsep="0" valign="bottom">98,770</entry></row><row><entry colsep="0" rowsep="0">48</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,257</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,571</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,464</entry><entry char="." colsep="0" rowsep="0" valign="bottom">17,279</entry><entry char="." colsep="0" rowsep="0" valign="bottom">19,748</entry><entry char="." colsep="0" rowsep="0" valign="bottom">22,216</entry><entry colsep="0" rowsep="0" valign="bottom">24,684</entry></row><row><entry colsep="0" rowsep="0">49</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,171</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,715</entry><entry char="." colsep="0" rowsep="0" valign="bottom">9,644</entry><entry char="." colsep="0" rowsep="0" valign="bottom">11,520</entry><entry char="." colsep="0" rowsep="0" valign="bottom">13,166</entry><entry char="." colsep="0" rowsep="0" valign="bottom">14,811</entry><entry colsep="0" rowsep="0" valign="bottom">16,456</entry></row><row><entry colsep="0" rowsep="0">50</entry><entry colsep="0" rowheader="yes" rowsep="0">Preclinical submission</entry><entry colsep="0" rowsep="0">Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,086</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,858</entry><entry char="." colsep="0" rowsep="0" valign="bottom">4,823</entry><entry char="." colsep="0" rowsep="0" valign="bottom">5,760</entry><entry char="." colsep="0" rowsep="0" valign="bottom">6,584</entry><entry char="." colsep="0" rowsep="0" valign="bottom">7,407</entry><entry colsep="0" rowsep="0" valign="bottom">8,229</entry></row><row><entry colsep="0" rowsep="0">51</entry><entry colsep="0" rowheader="yes" rowsep="0">Sale of new drug for emergency treatment</entry><entry colsep="0" rowsep="0">Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry char="." colsep="0" rowsep="0" valign="bottom">51</entry><entry colsep="0" rowsep="0" valign="bottom">51</entry></row><row><entry colsep="0" rowsep="0">52</entry><entry colsep="0" rowheader="yes" rowsep="0">Sale of new drug for emergency treatment</entry><entry colsep="0" rowsep="0">Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry char="." colsep="0" rowsep="0" valign="bottom">102</entry><entry colsep="0" rowsep="0" valign="bottom">102</entry></row><row><entry colsep="0" rowsep="0">53</entry><entry colsep="0" rowheader="yes" rowsep="0">Experimental studies certificate</entry><entry colsep="0" rowsep="0">Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry char="." colsep="0" rowsep="0" valign="bottom">980</entry><entry colsep="0" rowsep="0" valign="bottom">980</entry></row><row><entry colsep="0" rowsep="0">54</entry><entry colsep="0" rowheader="yes" rowsep="0">Experimental studies certificate</entry><entry colsep="0" rowsep="0">Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry colsep="0" rowsep="0" valign="bottom">490</entry></row><row><entry colsep="0" rowsep="0">55</entry><entry colsep="0" rowheader="yes" rowsep="0">Experimental studies certificate</entry><entry colsep="0" rowsep="0">Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,958</entry><entry colsep="0" rowsep="0" valign="bottom">2,958</entry></row><row><entry colsep="0" rowsep="0">56</entry><entry colsep="0" rowheader="yes" rowsep="0">Experimental studies certificate</entry><entry colsep="0" rowsep="0">Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry char="." colsep="0" rowsep="0" valign="bottom">490</entry><entry colsep="0" rowsep="0" valign="bottom">490</entry></row><row><entry colsep="0" rowsep="0">57</entry><entry colsep="0" rowheader="yes" rowsep="0">Notifiable change</entry><entry colsep="0" rowsep="0">Information and material to support an application for a notifiable change</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,658</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,073</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,591</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,095</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,537</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,978</entry><entry colsep="0" rowsep="0" valign="bottom">4,420</entry></row><row><entry colsep="0" rowsep="0">58</entry><entry colsep="0" rowheader="yes" rowsep="0">Protocol</entry><entry colsep="0" rowsep="0">A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate</entry><entry char="." colsep="0" rowsep="0" valign="bottom">1,658</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,073</entry><entry char="." colsep="0" rowsep="0" valign="bottom">2,591</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,095</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,537</entry><entry char="." colsep="0" rowsep="0" valign="bottom">3,978</entry><entry colsep="0" rowsep="0" valign="bottom">4,420</entry></row></tbody></tgroup></table><Footnote id="fn_1" placement="table" status="official"><Label>1</Label><Text>This item applies only to an application for a drug identification number that does not include either of the components set out in items 1 and 2.</Text></Footnote><Footnote id="fn_2" placement="table" status="official"><Label>2</Label><Text>This item applies only to a new drug submission that does not include any of the components set out in items 5 to 17.</Text></Footnote><Footnote id="fn_3" placement="table" status="official"><Label>3</Label><Text>This item applies only to a supplement to a new drug submission that does not include any of the components set out in items 19 to 36.</Text></Footnote><Footnote id="fn_4" placement="table" status="official"><Label>4</Label><Text>This item applies only to an abbreviated new drug submission or a supplement to an abbreviated new drug submission that does not include any of the components set out in items 38 to 41.</Text></Footnote></TableGroup></Schedule><Schedule lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:lastAmendedDate="2025-05-31" lims:fid="1531449" lims:id="1531449" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531450" lims:id="1531450"><Label>SCHEDULE 2.1</Label><OriginatingRef>(Subsection <XRefInternal>27.2(1)</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531451" lims:id="1531451" pointsize="8" topmarginspacing="10"><table lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531452" lims:id="1531452" frame="topbot"><title lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531453" lims:id="1531453">Fees for Examination of an Application — Biocides</title><tgroup lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531454" lims:id="1531454" cols="4"><colspec colname="COLSPEC10" colwidth="91.36*" /><colspec colname="COLSPEC9" colwidth="359.83*" /><colspec colname="COLSPEC0" colwidth="359.50*" /><colspec colname="COLSPEC5" colwidth="209.95*" /><thead lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531455" lims:id="1531455"><row topdouble="yes"><entry align="justify" colsep="0" rowsep="0" valign="top" /><entry align="justify" colsep="0" rowsep="0" valign="top">Column 1</entry><entry align="justify" colsep="0" rowsep="0" valign="top">Column 2</entry><entry align="justify" colsep="0" rowsep="0" valign="top">Column 3</entry></row><row><entry align="justify" colsep="0">Item</entry><entry align="justify" colsep="0">Class</entry><entry align="justify" colsep="0" rowsep="1" valign="bottom">Description</entry><entry align="justify" colsep="0">Fee ($)</entry></row></thead><tbody lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531456" lims:id="1531456"><row><entry colsep="0" rowsep="0">1</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide full review — novel biocide</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change, other than an application based on a comparison referred to in item 7, if the biocide has a novel active ingredient, a novel combination of active ingredients, or a novel physical form, use, purpose or method of application</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">41,685</entry></row><row><entry colsep="0" rowsep="0">2</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide full review — tier I</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change, other than an application referred to in item 1, that contains 25 or fewer reports of tests and studies with respect to efficacy data</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">8,595</entry></row><row><entry colsep="0" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide full review — tier II</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change, other than an application referred to in item 1, that contains 26 to 50 reports of tests and studies with respect to efficacy data</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">11,469</entry></row><row><entry colsep="0" rowsep="0">4</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide full review — tier III</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change, other than an application referred to in item 1, that contains at least 51 reports of tests and studies with respect to efficacy data</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">13,523</entry></row><row><entry colsep="0" rowsep="0">5</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide comparison — labelling only</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change that is based on a comparison and requires a review of labelling</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">2,748</entry></row><row><entry colsep="0" rowsep="0">6</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide comparison — administrative application</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change that is based on a comparison between the biocide and another biocide that is the subject of a market authorization in cases where only the brand name of the biocide, the name of the applicant or the name of the holder of the market authorization, or any combination thereof, differs from the corresponding information in respect of the other biocide</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">975</entry></row><row><entry colsep="0" rowsep="0">7</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide — use of foreign decisions</entry><entry colsep="0" rowsep="0">An application for a market authorization that is based on a comparison between the biocide and a biocide that is authorized for sale by a foreign regulatory authority or an application for a notice of acceptance in respect of a major change to the biocide that is the subject of such a market authorization</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">3,100</entry></row><row><entry colsep="0" rowsep="0">8</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide monograph</entry><entry colsep="0" rowsep="0">An application for a market authorization or for a notice of acceptance in respect of a major change that includes an attestation of compliance with a biocide monograph prepared by the Minister and requires supporting information for aspects of the biocide that are outside the parameters of the monograph</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">1,861</entry></row><row><entry colsep="0" rowsep="0">9</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide major change — monograph</entry><entry colsep="0" rowsep="0">An application for a notice of acceptance in respect of a major change that includes an attestation of compliance with a biocide monograph prepared by the Minister and that does not require supporting information because the aspects of the biocide that are impacted by the change are within the parameters of the monograph</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">1,363</entry></row><row><entry colsep="0" rowsep="0">10</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide major change — quality and risks</entry><entry colsep="0" rowsep="0">An application for a notice of acceptance in respect of a major change that does not include reports of tests and studies with respect to efficacy data</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">4,955</entry></row><row><entry colsep="0" rowsep="0">11</entry><entry colsep="0" rowheader="yes" rowsep="0">Biocide minor change</entry><entry colsep="0" rowsep="0">The examination of a written description of a minor change</entry><entry colsep="0" rowheader="no" rowsep="0" valign="bottom">1,363</entry></row></tbody></tgroup></table></TableGroup><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2025-05-31" lims:enacted-date="2024-06-04" lims:fid="1531458" lims:id="1531458" lims:enactId="1456194">SOR/2024-121, s. 10</HistoricalNoteSubItem></HistoricalNote></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129204" lims:id="1129204" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129205" lims:id="1129205"><Label>SCHEDULE 3</Label><OriginatingRef>(Sections <XRefInternal>33</XRefInternal> to <XRefInternal>39</XRefInternal> and <XRefInternal>41</XRefInternal> to <XRefInternal>47</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129206" lims:id="1129206" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129207" lims:id="1129207" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129208" lims:id="1129208">Fees for Examination of an Application for an Establishment Licence — Drugs for Human Use</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129209" lims:id="1129209" cols="6"><colspec colname="COLSPEC6" colwidth="66.90*" /><colspec colname="2" colwidth="555.07*" /><colspec colname="COLSPEC1" colwidth="162.69*" /><colspec colname="COLSPEC2" colwidth="163.57*" /><colspec colname="COLSPEC3" colwidth="160.94*" /><colspec colname="COLSPEC4" colwidth="161.81*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129210" lims:id="1129210"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry colsep="0" rowsep="0" valign="top">Column 3</entry><entry colsep="0" rowsep="0" valign="top">Column 4</entry><entry colsep="0" rowsep="0" valign="top">Column 5</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Activity</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry colsep="0" valign="bottom">2020-2021</entry><entry colsep="0" valign="bottom">2021-2022</entry><entry colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129211" lims:id="1129211"><row><entry colsep="0" rowheader="no" rowsep="0">1</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Fabrication — sterile dosage form</entry><entry colsep="0" rowheader="no" rowsep="0">41,626</entry><entry colsep="0" rowheader="no" rowsep="0">41,730</entry><entry colsep="0" rowheader="no" rowsep="0">41,834</entry><entry colsep="0" rowheader="no" rowsep="0">41,937</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">2</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Importation</entry><entry colsep="0" rowheader="no" rowsep="0">27,359</entry><entry colsep="0" rowheader="no" rowsep="0">29,033</entry><entry colsep="0" rowheader="no" rowsep="0">30,707</entry><entry colsep="0" rowheader="no" rowsep="0">32,380</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Fabrication — non-sterile dosage form</entry><entry colsep="0" rowheader="no" rowsep="0">27,000</entry><entry colsep="0" rowheader="no" rowsep="0">28,364</entry><entry colsep="0" rowheader="no" rowsep="0">29,727</entry><entry colsep="0" rowheader="no" rowsep="0">31,091</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">4</entry><entry colsep="0" rowheader="yes" rowsep="0">Distribution</entry><entry colsep="0" rowheader="no" rowsep="0">12,560</entry><entry colsep="0" rowheader="no" rowsep="0">13,882</entry><entry colsep="0" rowheader="no" rowsep="0">15,205</entry><entry colsep="0" rowheader="no" rowsep="0">16,527</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">5</entry><entry colsep="0" rowheader="yes" rowsep="0">Wholesaling</entry><entry colsep="0" rowheader="no" rowsep="0">4,937</entry><entry colsep="0" rowheader="no" rowsep="0">6,171</entry><entry colsep="0" rowheader="no" rowsep="0">7,715</entry><entry colsep="0" rowheader="no" rowsep="0">9,644</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">6</entry><entry colsep="0" rowheader="yes" rowsep="0">Packaging/labelling</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">7</entry><entry colsep="0" rowheader="yes" rowsep="0">Testing</entry><entry colsep="0" rowheader="no" rowsep="0">2,560</entry><entry colsep="0" rowheader="no" rowsep="0">3,200</entry><entry colsep="0" rowheader="no" rowsep="0">4,001</entry><entry colsep="0" rowheader="no" rowsep="0">5,002</entry></row></tbody></tgroup></table></TableGroup></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129212" lims:id="1129212" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129213" lims:id="1129213"><Label>SCHEDULE 4</Label><OriginatingRef>(Sections <XRefInternal>33</XRefInternal> to <XRefInternal>39</XRefInternal> and <XRefInternal>41</XRefInternal> to <XRefInternal>47</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129214" lims:id="1129214" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129215" lims:id="1129215" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129216" lims:id="1129216">Fees for Examination of an Application for an Establishment Licence — Drugs for Veterinary Use Only</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129217" lims:id="1129217" cols="9"><colspec colname="COLSPEC6" colwidth="100.69*" /><colspec colname="2" colwidth="295.05*" /><colspec colname="COLSPEC1" colwidth="227.30*" /><colspec colname="COLSPEC2" colwidth="222.79*" /><colspec colname="COLSPEC3" colwidth="209.24*" /><colspec colname="COLSPEC7" colwidth="219.78*" /><colspec colname="COLSPEC5" colwidth="209.24*" /><colspec colname="COLSPEC0" colwidth="209.24*" /><colspec colname="COLSPEC4" colwidth="210.74*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129218" lims:id="1129218"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry colsep="0" rowsep="0" valign="top">Column 3</entry><entry colsep="0" rowsep="0" valign="top">Column 4</entry><entry colsep="0" rowsep="0" valign="top">Column 5</entry><entry colsep="0" rowsep="0" valign="top">Column 6</entry><entry colsep="0" rowsep="0" valign="top">Column 7</entry><entry colsep="0" rowsep="0" valign="top">Column 8</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Activity</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry colsep="0" valign="bottom">2020-2021</entry><entry colsep="0" valign="bottom">2021-2022</entry><entry colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry><entry colsep="0" valign="bottom">2024-2025</entry><entry colsep="0" valign="bottom">2025-2026</entry><entry colsep="0" valign="bottom">2026-2027</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129219" lims:id="1129219"><row><entry colsep="0" rowheader="no" rowsep="0">1</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Fabrication — sterile dosage form</entry><entry colsep="0" rowheader="no" rowsep="0">40,198</entry><entry colsep="0" rowheader="no" rowsep="0">40,487</entry><entry colsep="0" rowheader="no" rowsep="0">40,777</entry><entry colsep="0" rowheader="no" rowsep="0">41,068</entry><entry colsep="0" rowheader="no" rowsep="0">41,357</entry><entry colsep="0" rowheader="no" rowsep="0">41,647</entry><entry colsep="0" rowheader="no" rowsep="0">41,937</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">2</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Importation</entry><entry colsep="0" rowheader="no" rowsep="0">10,715</entry><entry colsep="0" rowheader="no" rowsep="0">13,393</entry><entry colsep="0" rowheader="no" rowsep="0">16,742</entry><entry colsep="0" rowheader="no" rowsep="0">20,927</entry><entry colsep="0" rowheader="no" rowsep="0">26,158</entry><entry colsep="0" rowheader="no" rowsep="0">32,380</entry><entry colsep="0" rowheader="no" rowsep="0">32,380</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Fabrication — non-sterile dosage form</entry><entry colsep="0" rowheader="no" rowsep="0">8,782</entry><entry colsep="0" rowheader="no" rowsep="0">10,978</entry><entry colsep="0" rowheader="no" rowsep="0">13,722</entry><entry colsep="0" rowheader="no" rowsep="0">17,152</entry><entry colsep="0" rowheader="no" rowsep="0">21,440</entry><entry colsep="0" rowheader="no" rowsep="0">26,800</entry><entry colsep="0" rowheader="no" rowsep="0">31,091</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">4</entry><entry colsep="0" rowheader="yes" rowsep="0">Distribution</entry><entry colsep="0" rowheader="no" rowsep="0">4,835</entry><entry colsep="0" rowheader="no" rowsep="0">6,043</entry><entry colsep="0" rowheader="no" rowsep="0">7,555</entry><entry colsep="0" rowheader="no" rowsep="0">9,443</entry><entry colsep="0" rowheader="no" rowsep="0">11,803</entry><entry colsep="0" rowheader="no" rowsep="0">14,754</entry><entry colsep="0" rowheader="no" rowsep="0">16,527</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">5</entry><entry colsep="0" rowheader="yes" rowsep="0">Wholesaling</entry><entry colsep="0" rowheader="no" rowsep="0">1,933</entry><entry colsep="0" rowheader="no" rowsep="0">2,416</entry><entry colsep="0" rowheader="no" rowsep="0">3,020</entry><entry colsep="0" rowheader="no" rowsep="0">3,774</entry><entry colsep="0" rowheader="no" rowsep="0">4,718</entry><entry colsep="0" rowheader="no" rowsep="0">5,898</entry><entry colsep="0" rowheader="no" rowsep="0">7,372</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">6</entry><entry colsep="0" rowheader="yes" rowsep="0">Packaging/labelling</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry><entry colsep="0" rowheader="no" rowsep="0">6,061</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">7</entry><entry colsep="0" rowheader="yes" rowsep="0">Testing</entry><entry colsep="0" rowheader="no" rowsep="0">1,315</entry><entry colsep="0" rowheader="no" rowsep="0">1,644</entry><entry colsep="0" rowheader="no" rowsep="0">2,055</entry><entry colsep="0" rowheader="no" rowsep="0">2,569</entry><entry colsep="0" rowheader="no" rowsep="0">3,210</entry><entry colsep="0" rowheader="no" rowsep="0">4,013</entry><entry colsep="0" rowheader="no" rowsep="0">5,002</entry></row></tbody></tgroup></table></TableGroup></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129220" lims:id="1129220" bilingual="no" spanlanguages="no"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129221" lims:id="1129221"><Label>SCHEDULE 5</Label><OriginatingRef>(Section <XRefInternal>48</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129222" lims:id="1129222" pointsize="8" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129223" lims:id="1129223" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129224" lims:id="1129224">Fee Reduction — Application for an Establishment Licence — Drugs</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129225" lims:id="1129225" cols="3"><colspec colname="COLSPEC0" colwidth="89.39*" /><colspec colname="COLSPEC2" colwidth="267.23*" /><colspec colname="COLSPEC4" colwidth="280.67*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129226" lims:id="1129226"><row topdouble="yes"><entry colsep="0" morerows="1" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry></row><row><entry colsep="0" valign="bottom">Percentage of Fee Reduction</entry><entry colsep="0" valign="bottom">Filing Period</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129227" lims:id="1129227"><row><entry colsep="0" rowheader="no" rowsep="0">1</entry><entry colsep="0" rowheader="no" rowsep="0">25%</entry><entry colsep="0" rowheader="no" rowsep="0">July 1 to September 30</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">2</entry><entry colsep="0" rowheader="no" rowsep="0">50%</entry><entry colsep="0" rowheader="no" rowsep="0">October 1 to December 31</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">3</entry><entry colsep="0" rowheader="no" rowsep="0">75%</entry><entry colsep="0" rowheader="no" rowsep="0">January 1 to March 31</entry></row></tbody></tgroup></table></TableGroup><Provision lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129228" lims:id="1129228" format-ref="indent-0-0"><Label>Note:</Label><Text>The fee payable under subsection 30(1) of this Order is not reduced if an application is filed on or after April 1 and up to and including June 30.</Text></Provision></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129229" lims:id="1129229" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129230" lims:id="1129230"><Label>SCHEDULE 6</Label><OriginatingRef>(Section <XRefInternal>52</XRefInternal>)</OriginatingRef><TitleText>Fees for Right to Sell Drugs for Human Use</TitleText></ScheduleFormHeading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129231" lims:id="1129231" level="1"><TitleText>Interpretation</TitleText></Heading><RegulationPiece lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129232" lims:id="1129232"><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129233" lims:id="1129233"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129234" lims:id="1129234">Definition of <DefinitionRef>disinfectant</DefinitionRef></MarginalNote><Label>1</Label><Text lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1457315" lims:id="1457315">In this Schedule, <DefinedTermEn>disinfectant</DefinedTermEn> has the meaning assigned by the definition <DefinitionRef>antimicrobial agent</DefinitionRef> in subsection C.01A.001(1) of the <XRefExternal reference-type="regulation" link="C.R.C.,_c._870">Food and Drug Regulations</XRefExternal>.</Text><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129235" lims:id="1129235" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129236" lims:id="1129236" frame="topbot"><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129237" lims:id="1129237" cols="6"><colspec colname="COLSPEC6" colwidth="69.00*" /><colspec colname="2" colwidth="551.99*" /><colspec colname="COLSPEC1" colwidth="157.38*" /><colspec colname="COLSPEC2" colwidth="165.14*" /><colspec colname="COLSPEC3" colwidth="164.43*" /><colspec colname="COLSPEC4" colwidth="163.02*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129238" lims:id="1129238"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry colsep="0" rowsep="0" valign="top">Column 3</entry><entry colsep="0" rowsep="0" valign="top">Column 4</entry><entry colsep="0" rowsep="0" valign="top">Column 5</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Type of Drug</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry colsep="0" valign="bottom">2020-2021</entry><entry colsep="0" valign="bottom">2021-2022</entry><entry colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129239" lims:id="1129239"><row lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1457316" lims:id="1457316"><entry colsep="0" rowheader="no" rowsep="0">1</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Disinfectant</entry><entry colsep="0" rowheader="no" rowsep="0">1,285</entry><entry colsep="0" rowheader="no" rowsep="0">1,344</entry><entry colsep="0" rowheader="no" rowsep="0">1,403</entry><entry colsep="0" rowheader="no" rowsep="0">1,462</entry></row><row><entry colsep="0" rowheader="no" rowsep="0">2</entry><entry colsep="0" rowheader="yes" rowsep="0">Non-prescription drug</entry><entry colsep="0" rowheader="no" rowsep="0">1,623</entry><entry colsep="0" rowheader="no" rowsep="0">2,022</entry><entry colsep="0" rowheader="no" rowsep="0">2,421</entry><entry colsep="0" rowheader="no" rowsep="0">2,820</entry></row><row lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1457317" lims:id="1457317"><entry colsep="0" rowheader="no" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Drug other than one referred to in item 1 or 2</entry><entry colsep="0" rowheader="no" rowsep="0">1,836</entry><entry colsep="0" rowheader="no" rowsep="0">2,754</entry><entry colsep="0" rowheader="no" rowsep="0">4,080</entry><entry colsep="0" rowheader="no" rowsep="0">4,679</entry></row></tbody></tgroup></table></TableGroup></Section></RegulationPiece></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2020-04-01" lims:fid="1129240" lims:id="1129240" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129241" lims:id="1129241"><Label>SCHEDULE 7</Label><OriginatingRef>(Section <XRefInternal>56</XRefInternal>)</OriginatingRef></ScheduleFormHeading><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129242" lims:id="1129242" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129243" lims:id="1129243" frame="topbot"><title lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129244" lims:id="1129244">Fees for Right to Sell Drugs for Veterinary Use Only</title><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129245" lims:id="1129245" cols="5"><colspec colname="COLSPEC0" colwidth="56.82*" /><colspec colname="COLSPEC1" colwidth="239.61*" /><colspec colname="COLSPEC2" colwidth="259.65*" /><colspec colname="COLSPEC3" colwidth="254.64*" /><colspec colname="COLSPEC4" colwidth="247.96*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129246" lims:id="1129246"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry colsep="0" rowsep="0" valign="top">Column 3</entry><entry colsep="0" rowsep="0" valign="top">Column 4</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry colsep="0" valign="bottom">2020-2021</entry><entry colsep="0" valign="bottom">2021-2022</entry><entry colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129247" lims:id="1129247"><row><entry colsep="0" rowheader="no" rowsep="0">1</entry><entry colsep="0" rowheader="no" rowsep="0">312</entry><entry colsep="0" rowheader="no" rowsep="0">367</entry><entry colsep="0" rowheader="no" rowsep="0">422</entry><entry colsep="0" rowheader="no" rowsep="0">477</entry></row></tbody></tgroup></table></TableGroup></Schedule><Schedule lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2024-01-03" lims:fid="1129248" lims:id="1129248" bilingual="no" spanlanguages="yes"><ScheduleFormHeading lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129249" lims:id="1129249"><Label>SCHEDULE 8</Label><OriginatingRef>(Section <XRefInternal>60</XRefInternal>)</OriginatingRef><TitleText lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1390990" lims:id="1391076">Fees for Examination of an Application for a Licence, an Amendment Application for a Licence or an Application to Amend an Authorization — Medical Device</TitleText></ScheduleFormHeading><Heading lims:inforce-start-date="2019-05-08" lims:enacted-date="2019-05-08" lims:fid="1129250" lims:id="1129250" level="1"><TitleText>Interpretation</TitleText></Heading><RegulationPiece lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129251" lims:id="1129251"><Section lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:lastAmendedDate="2024-01-03" lims:fid="1129252" lims:id="1129252"><MarginalNote lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129253" lims:id="1129253">Definition of <DefinitionRef>private label medical device</DefinitionRef></MarginalNote><Label>1</Label><Text>In this Schedule, <DefinedTermEn>private label medical device</DefinedTermEn> means a medical device that is identical in every respect to a medical device in respect of which a licence has been issued, except that the device is labelled with the name and address of another manufacturer and the name and identifier of the device that the other manufacturer is proposing to sell under its own name or under a trademark, design, trade-name or other name or mark owned or controlled by it.</Text></Section></RegulationPiece><TableGroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129254" lims:id="1129254" pointsize="7" topmarginspacing="10"><table lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129255" lims:id="1129255" frame="topbot"><tgroup lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129256" lims:id="1129256" cols="7"><colspec colname="COLSPEC0" colwidth="81.63*" /><colspec colname="2" colwidth="230.23*" /><colspec colname="COLSPEC5" colwidth="308.17*" /><colspec colname="COLSPEC1" colwidth="216.35*" /><colspec colname="COLSPEC2" colwidth="216.35*" /><colspec colname="COLSPEC3" colwidth="215.27*" /><colspec colname="COLSPEC4" colwidth="214.20*" /><thead lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129257" lims:id="1129257"><row topdouble="yes"><entry colsep="0" morerows="3" rowsep="1" valign="bottom">Item</entry><entry colsep="0" rowsep="0" valign="top">Column 1</entry><entry colsep="0" rowsep="0" valign="top">Column 2</entry><entry colsep="0" rowsep="0" valign="top">Column 3</entry><entry colsep="0" rowsep="0" valign="top">Column 4</entry><entry colsep="0" rowsep="0" valign="top">Column 5</entry><entry colsep="0" rowsep="0" valign="top">Column 6</entry></row><row><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Category</entry><entry colsep="0" morerows="2" rowsep="1" valign="bottom">Description</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry><entry colsep="0" rowsep="0" valign="top">Fee ($)</entry></row><row><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry><entry colsep="0" rowsep="0" valign="top">Fiscal Year</entry></row><row><entry colsep="0" valign="bottom">2020-2021</entry><entry colsep="0" valign="bottom">2021-2022</entry><entry colsep="0" valign="bottom">2022-2023</entry><entry colsep="0" valign="bottom">2023-2024</entry></row></thead><tbody lims:inforce-start-date="2020-04-01" lims:enacted-date="2019-05-08" lims:fid="1129258" lims:id="1129258"><row><entry colsep="0" rowsep="0">1</entry><entry colname="2" colsep="0" rowheader="yes" rowsep="0" valign="top">Applications for Class II licence</entry><entry colsep="0" rowsep="0">Applications for Class II medical device licence other than those referred to in item 10</entry><entry colsep="0" rowheader="no" rowsep="0">450</entry><entry colsep="0" rowheader="no" rowsep="0">478</entry><entry colsep="0" rowheader="no" rowsep="0">505</entry><entry colsep="0" rowheader="no" rowsep="0">533</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390991" lims:id="1436532"><entry colsep="0" rowsep="0">2</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class II licence amendment or applications to amend Class II authorization</entry><entry colsep="0" rowsep="0">Applications for amendment of Class II medical device licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for a Class II medical device that is not a UPHN medical device, other than applications referred to in item 10</entry><entry colsep="0" rowheader="no" rowsep="0">272</entry><entry colsep="0" rowheader="no" rowsep="0">272</entry><entry colsep="0" rowheader="no" rowsep="0">272</entry><entry colsep="0" rowheader="no" rowsep="0">272</entry></row><row><entry colsep="0" rowsep="0">3</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class III licence</entry><entry colsep="0" rowsep="0">Applications for Class III medical device licence other than those referred to in item 4 or 10</entry><entry colsep="0" rowheader="no" rowsep="0">7,477</entry><entry colsep="0" rowheader="no" rowsep="0">8,912</entry><entry colsep="0" rowheader="no" rowsep="0">10,347</entry><entry colsep="0" rowheader="no" rowsep="0">11,783</entry></row><row><entry colsep="0" rowsep="0">4</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class III licence (near patient)</entry><entry colsep="0" rowsep="0">Applications for Class III medical device licence for a near patient in vitro diagnostic device</entry><entry colsep="0" rowheader="no" rowsep="0">12,851</entry><entry colsep="0" rowheader="no" rowsep="0">16,064</entry><entry colsep="0" rowheader="no" rowsep="0">20,081</entry><entry colsep="0" rowheader="no" rowsep="0">25,102</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390992" lims:id="1436539"><entry colsep="0" rowsep="0">5</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class III licence amendment or applications to amend Class III authorization — changes in manufacturing</entry><entry colsep="0" rowsep="0">Applications for amendment of Class III medical device licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for a Class III medical device that is not a UPHN medical device — changes in manufacturing process, facility or equipment or manufacturing quality control procedures</entry><entry colsep="0" rowheader="no" rowsep="0">1,903</entry><entry colsep="0" rowheader="no" rowsep="0">2,379</entry><entry colsep="0" rowheader="no" rowsep="0">2,974</entry><entry colsep="0" rowheader="no" rowsep="0">3,717</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390993" lims:id="1436538"><entry colsep="0" rowsep="0">6</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class III licence amendment or applications to amend Class III authorization — significant changes not related to manufacturing</entry><entry colsep="0" rowsep="0">Applications for amendment of Class III medical device licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for a Class III medical device that is not a UPHN medical device — significant changes other than those referred to in item 5</entry><entry colsep="0" rowheader="no" rowsep="0">6,608</entry><entry colsep="0" rowheader="no" rowsep="0">7,558</entry><entry colsep="0" rowheader="no" rowsep="0">8,508</entry><entry colsep="0" rowheader="no" rowsep="0">9,458</entry></row><row><entry colsep="0" rowsep="0">7</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class IV licence</entry><entry colsep="0" rowsep="0">Applications for Class IV medical device licence other than those referred to in item 10</entry><entry colsep="0" rowheader="no" rowsep="0">24,345</entry><entry colsep="0" rowheader="no" rowsep="0">24,748</entry><entry colsep="0" rowheader="no" rowsep="0">25,151</entry><entry colsep="0" rowheader="no" rowsep="0">25,554</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390994" lims:id="1436541"><entry colsep="0" rowsep="0">8</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class IV licence amendment or applications to amend Class IV authorization — changes in manufacturing</entry><entry colsep="0" rowsep="0">Applications for amendment of Class IV medical device licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for a Class IV medical device that is not a UPHN medical device — changes referred to in paragraph 34(a) or 68.13(a) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> that relate to manufacturing</entry><entry colsep="0" rowheader="no" rowsep="0">1,903</entry><entry colsep="0" rowheader="no" rowsep="0">2,379</entry><entry colsep="0" rowheader="no" rowsep="0">2,974</entry><entry colsep="0" rowheader="no" rowsep="0">3,717</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390995" lims:id="1436540"><entry colsep="0" rowsep="0">9</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class IV licence amendment or applications to amend Class IV authorization — significant changes not related to manufacturing</entry><entry colsep="0" rowsep="0">Applications for amendment of Class IV medical device licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for Class IV medical device that is not a UPHN medical device — any other changes referred to in paragraph 34(a) or (b) or 68.13(a) or (b) of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal></entry><entry colsep="0" rowheader="no" rowsep="0">8,057</entry><entry colsep="0" rowheader="no" rowsep="0">9,983</entry><entry colsep="0" rowheader="no" rowsep="0">11,752</entry><entry colsep="0" rowheader="no" rowsep="0">13,521</entry></row><row lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1390996" lims:id="1436543"><entry colsep="0" rowsep="0">10</entry><entry colsep="0" rowheader="yes" rowsep="0">Applications for Class II, III or Class IV licence, applications to amend such a licence or applications to amend Class II, III or Class IV authorization — private label medical device</entry><entry colsep="0" rowsep="0">Applications for Class II, III or IV medical device licence, applications to amend Class II, III or IV licence or applications to amend authorization filed under section 68.14 of the <XRefExternal reference-type="regulation" link="SOR-98-282">Medical Devices Regulations</XRefExternal> for a Class II, III or Class IV medical device that is not a UPHN medical device — private label medical device</entry><entry colsep="0" rowheader="no" rowsep="0">147</entry><entry colsep="0" rowheader="no" rowsep="0">147</entry><entry colsep="0" rowheader="no" rowsep="0">147</entry><entry colsep="0" rowheader="no" rowsep="0">147</entry></row></tbody></tgroup></table></TableGroup><HistoricalNote><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391078" lims:id="1391078" lims:enactId="1390967">SOR/2023-21, s. 8</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2023-02-22" lims:enacted-date="2023-02-06" lims:fid="1391085" lims:id="1391085" lims:enactId="1390969">SOR/2023-21, s. 9</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436533" lims:id="1436533" lims:enactId="1435013">SOR/2023-278, s. 5</HistoricalNoteSubItem><HistoricalNoteSubItem lims:inforce-start-date="2024-01-03" lims:enacted-date="2023-12-19" lims:fid="1436542" lims:id="1436542" lims:enactId="1435015">SOR/2023-278, s. 6</HistoricalNoteSubItem></HistoricalNote></Schedule><Schedule id="RelatedProvs"><ScheduleFormHeading type="amending"><TitleText>RELATED PROVISIONS</TitleText></ScheduleFormHeading><RegulationPiece><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 14</TitleText></Heading><Section><Label>14</Label><Text>A person that submits an application, under subsection 10(1) of the <XRefExternal reference-type="regulation" link="SOR-2024-110">Biocides Regulations</XRefExternal>, for a market authorization for a <DefinitionRef>biocide</DefinitionRef>, as defined in subsection 1(1) of those Regulations, is not required to pay the fee for the examination of the application referred to in subsection <XRefInternal>27.2</XRefInternal>(1) of the <XRefExternal reference-type="regulation" link="SOR-2019-124">Fees in Respect of Drugs and Medical Devices Order</XRefExternal> if the biocide is the subject of one of the exceptions set out in section 67 or 69 of those Regulations.</Text></Section></RelatedOrNotInForce></RegulationPiece></Schedule><Schedule id="NifProvs"><ScheduleFormHeading type="amending"><TitleText>AMENDMENTS NOT IN FORCE</TitleText></ScheduleFormHeading><RegulationPiece><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 8</TitleText></Heading><Section type="amending"><Label>8</Label><Text>Items 10 and 11 of Schedule 1 to the Order are repealed.</Text></Section></RelatedOrNotInForce><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 9</TitleText></Heading><Section type="amending"><Label>9</Label><Text>The portion of item 1 of Schedule 1 to the Order in column 2 is replaced by the following:</Text><AmendedText><TableGroup pointsize="8" topmarginspacing="10"><table frame="topbot"><tgroup cols="2"><colspec colname="1" colwidth="54.94*" /><colspec colname="3" colwidth="412.82*" /><thead><row topdouble="yes" topmarginspacing="4"><entry colsep="0" rowsep="0" valign="top" /><entry colsep="0" rowsep="0" valign="top"><Emphasis style="bold">Column 2</Emphasis></entry></row><row topmarginspacing="6"><entry colsep="0" rowsep="1" valign="bottom"><Emphasis style="bold">Item</Emphasis></entry><entry colsep="0" rowsep="1" valign="bottom"><Emphasis style="bold">Description</Emphasis></entry></row></thead><tbody><row topmarginspacing="4"><entry colname="1" colsep="0" rowsep="0" valign="top"><Emphasis style="bold">1</Emphasis></entry><entry colname="3" colsep="0" rowsep="0" valign="top">Submissions in support of a drug that contains a medicinal ingredient not previously approved in a drug for sale in Canada and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph<Sup>1</Sup></entry></row></tbody></tgroup></table></TableGroup></AmendedText></Section></RelatedOrNotInForce><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 11</TitleText></Heading><Section type="amending"><Label>11</Label><Text>Section 1 and the heading before it of Schedule 6 to the Order are repealed.</Text></Section></RelatedOrNotInForce><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 12</TitleText></Heading><Section type="amending"><Label>12</Label><Text>Item 1 of Schedule 6 to the Order is repealed.</Text></Section></RelatedOrNotInForce><RelatedOrNotInForce><Heading level="5" style="nifrp"><TitleText>
                    — SOR/2024-121, s. 13</TitleText></Heading><Section type="amending"><Label>13</Label><Text>The portion of item 3 of Schedule 6 to the Order in column 1 is replaced by the following:</Text><AmendedText><TableGroup pointsize="8" topmarginspacing="10"><table frame="topbot"><tgroup cols="2"><colspec colname="1" colwidth="54.94*" /><colspec colname="3" colwidth="412.82*" /><thead><row topdouble="yes" topmarginspacing="4"><entry colsep="0" rowsep="0" valign="top" /><entry colsep="0" rowsep="0" valign="top"><Emphasis style="bold">Column 1</Emphasis></entry></row><row topmarginspacing="6"><entry colsep="0" rowsep="1" valign="bottom"><Emphasis style="bold">Item</Emphasis></entry><entry colsep="0" rowsep="1" valign="bottom"><Emphasis style="bold">Description</Emphasis></entry></row></thead><tbody><row topmarginspacing="4"><entry colname="1" colsep="0" rowsep="0" valign="top"><Emphasis style="bold">3</Emphasis></entry><entry colname="3" colsep="0" rowsep="0" valign="top">Drug, other than a biocide and other than one referred to in item 2</entry></row></tbody></tgroup></table></TableGroup></AmendedText></Section></RelatedOrNotInForce></RegulationPiece></Schedule><RecentAmendments><Amendment><AmendmentCitation>SOR/2024-121</AmendmentCitation><AmendmentDate>2025-05-31</AmendmentDate></Amendment><Amendment><AmendmentCitation>SOR/2024-247</AmendmentCitation><AmendmentDate>2024-12-18</AmendmentDate></Amendment><Amendment><AmendmentCitation>SOR/2023-278</AmendmentCitation><AmendmentDate>2024-01-03</AmendmentDate></Amendment><Amendment><AmendmentCitation>SOR/2023-21</AmendmentCitation><AmendmentDate>2023-02-22</AmendmentDate></Amendment><Amendment><AmendmentCitation>SOR/2021-47</AmendmentCitation><AmendmentDate>2021-03-19</AmendmentDate></Amendment></RecentAmendments></Regulation>